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Abstract 	
Parkinson’s disease (PD) is the most common neurodegenerative disorder with 
motor impairment. While PD is clinically well characterized, the molecular and 
cellular basis underlying both the onset and progression of the disorder are still 
unknown. Gaining deeper knowledge on PD pathophysiology has been hindered 
by the fact that only a minority of PD patients have a defined genetic cause, with 
the remaining 90% of the cases being classified as sporadic. Thus far, mutations 
in more than 20 genes are considered risk factors for developing PD. These PD-
related genes are linked to several distinct intracellular pathways, hardening the 
quest to pinpoint the exact molecular imbalance responsible for PD onset.  One of 
these pathways, the Endolysosomal, has recently gained notoriety due to its 
importance in alpha-Synuclein homeostasis (α-Syn). α-Syn is a small protein with 
unknown function and, perhaps, the most extensively studied in PD context. 
Several point mutations and gene multiplications in α-Syn gene, SNCA, have been 
linked to PD and the protein is found in Lewy Bodies (LB), the pathological 
hallmark of the disease.  In the Endolysosomal machinery another PD-associated 
protein has been under the spotlight: ATP13A2. This protein is a transmembrane 
ATPase located at the late endosomes and lysosomes, with yet unknown function, 
that is also present in LB. In the last years important steps have been taken 
towards understanding the interplay between ATP13A2 and α-Syn, with 
contradictory results reported. Inarguable though is that ATP13A2 can, at least 
partially, affect the intracellular fate of α-Syn.  
Our work confirms that the Endolysosomal pathway plays an important role in α-
Syn homeostasis. We start by showing that two proteins members of this pathway, 
Raba8a and ATP13A2, could alter α-Syn aggregation in a well-established cellular 
model. Nevertheless, while we found that Raba8a exerts its effect by direct binding 
to α-Syn, the PD-associated protein ATP13A2 may affect specific cellular 
mechanisms. We describe that, in human cells, a mutation in ATP13A2, a 
duplication of 22 base pairs (Dup22), enhances α-Syn aggregation and increases 
its resistance to proteinase K digestion. The mutated protein could also promote 
the formation of oligomers and higher α-Syn molecular weight species. In addition, 
the dynamics between α-Syn and ATP13A2 Dup22 can severely impact cellular 
homeostasis. Here we report that α-Syn and ATP13A2 Dup22 can be found in a 
	 xiv	
reticular, membranar structure, which we found to be composed by endoplasmic 
reticulum (ER). This alteration in the ER morphology was correlated with an 
unmitigated increase in ER stress that culminates with the activation of apoptotic 
pathways and cell death. Besides ER changes we also identified significant 
alterations in mitochondria morphology, along with increased susceptibility to 
oxidative stress. 
Altogether our work provides novel insights into the effect of Endolysosomal 
proteins on α-Syn. Additionally we describe that the interaction of two PD-
associated proteins, ATP13A2 and α-Syn, may trigger a cascade of deleterious 
intracellular events that involve ER stress and mitochondria alterations, and 
ultimately lead to cell death. Most importantly, our findings shed new light on the 
cellular dyshomeostasis that may underlie the development of PD. 																											
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Resumo 	
A doença de Parkinson (PD) é a condição neurodegenerativa com sintomas 
motores mais comum. Embora o quadro clínico da doença esteja bem 
caracterizado, os mecanismos moleculares e celulares responsáveis pelo seu 
aparecimento e progressão são ainda desconhecidos. O estudo aprofundado 
sobre a patofisiologia de PD tem sido  dificultado pelo escasso número de 
pacientes que apresentam uma causa genética definida, sendo que 
aproximadamente 90% dos casos são classificados como esporádicos. 
Atualmente, um total de 20 genes são considerados factores de risco para o 
aparecimento de PD. O envolvimento desses genes em diferentes mecanismos 
intracelulares confere complexidade adicional à investigação da causa da doença. 
Um desses mecanismos é a via endo-lisossomal, a qual tem recentemente ganho 
relevo devido à sua importância na homeostasia da proteína alpha-sinucleina (α-
Syn). A α-Syn é uma proteína com função desconhecida e, provavelmente, a mais 
estudada no contexto de PD. Várias mutações e multiplicações no gene da α-Syn, 
SNCA, foram descritas em doentes com PD e a proteína está presente nos 
Corpos de Lewy  (LBs), considerados um dos principais marcos histopatológicos 
da doença. A via endo-lisossomal é regulada por várias proteínas, sendo que a 
ATP13A2 tem merecido destaque por estar geneticamente associada a PD. Esta 
proteína é uma ATPase transmembranar com localização nos endossomas e 
lisossomas. À semelhança da α-Syn, a ATP13A2 é também encontrada nos LBs e 
a sua função é ainda desconhecida. 
Nos últimos anos têm sido dados passos importantes para melhor compreender a 
interação entre estas duas proteínas, embora resultados contraditórios tenham 
sido descritos. Apesar de algumas discrepâncias, é indiscutível que a ATP13A2 
afecta, pelo menos parcialmente, o destino intracelular da α-Syn. 
O nosso estudo confirma que a via endo-lisossomal desempenha um papel crucial 
na homeostasia da α-Syn. Inicialmente, mostramos que duas proteínas que 
intervêm nesta via, ATP13A2 e Raba8a, têm a capacidade de alterar a formação 
de inclusões intracelulares de α-Syn. No entanto, embora a Raba8a exerça o seu 
efeito através de uma interação direta com a α-Syn os nossos resultados indicam 
que a ATP13A2 afecta mecanismos intracelulares específicos. Em células 
humanas, uma mutação familiar na ATP13A2, que consiste na duplicação de 22 
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pares bases no gene (Dup22), aumenta a formação de inclusões de α-Syn e a 
sua resistência à digestão com proteinase K. Esta proteína mutada é também 
capaz de promover a formação de oligómeros e espécies de peso molecular 
superior de α-Syn. Paralelamente, a dinâmica de interação entre α-Syn e 
ATP13A2 Dup22 tem um efeito severo na homeostasia celular. Neste trabalho 
reportamos que a α-Syn e a ATP13A2 Dup22 co-localizam em estruturas 
reticulares membranosas, as quais descobrirmos serem compostas por reticulo 
endoplasmático (ER). Esta alteração da morfologia do ER está associada a um 
aumento do stress do ER, que culmina na ativação de mecanismos apoptóticos e 
morte celular. Para além do ER, também observámos alterações significativas na 
morfologia da mitocôndria acompanhada por um aumento de susceptibilidade a 
stress oxidativo. 
Em resumo, estes resultados oferecem novos conhecimentos sobre o efeito de 
proteínas associadas à via endo-lisossomal na homeostasis da α-Syn. 
Adicionalmente descrevemos que a interação de duas proteínas associadas a PD, 
ATP13A2 e α-Syn, ativa uma cascata perniciosa de eventos intracelulares que 
envolvem stress do ER e alterações na mitocôndria, e culminam em morte celular. 
Mais importante, estas descobertas fornecem uma melhor compreensão dos 
mecanismos celulares que poderão influenciar o aparecimento da doença de PD. 																				
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1. Introduction 	
The continuous improvement of life conditions and medical assistance worldwide, 
but particularly in developed countries, is bringing new challenges to the clinical 
community in particular, and to modern societies in general. One of these matters 
is that population aging is drastically increasing the occurrence of 
neurodegenerative diseases, which many now consider an epidemic. In this 
picture, it is important to take into consideration the deriving high medical costs 
that, just in Europe, reached more than 798 billion euros in 2010 (1). 
Understanding the micro- and macro-environmental alterations occurring in a 
neurodegenerative brain has gained enormous interest in the research field over 
the last century. The ultimate goal is to gather a deep understanding of the many 
faces of the neurodegeneration process and, ultimately, bring new treatments and 
therapeutics from bench to clinics. 
	
1.1. Parkinson’s Disease 
 
Parkinson’s disease (PD) was first described in 1817 by James Parkinson, and is 
nowadays the second most common neurodegenerative disorder after Alzheimer’s 
disease (2). At the clinical level, PD is classically characterized by motor 
symptoms that include bradykinesia, resting tremor, postural instability, and 
muscular rigidity (3) (Fig. 1A). Pathologically the degeneration of dopaminergic 
neurons in the substantia nigra (SN) pars compacta, and the presence of 
intracellular proteinaceous inclusions in the surviving neurons, known as Lewy 
Bodies (LBs) and Lewy Neurites (LNs) (3), are the main hallmarks of PD (Fig. 1B). 
Although initially classified as a movement disorder, it is now well accepted that 
non-motor symptoms can precede and succeed motor disabilities, and PD is 
currently regarded as a whole-brain disease (4). In fact, non-motor symptoms are 
gaining momentum in PD research for possible clinical biomarkers or predictors of 
the disease onset (5). Furthermore as the understanding on PD symptomatology 
evolves, the mechanisms underlying the pathological progression of the disease 
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come under spotlight. Despite lacking full validation, Braak’s staging theory is 
appraised as the most comprehensive data on PD progression. Braak 
hypothesises that PD pathology might start in either the olfactory bulb or in the 
lower brainstem. Later on, with the disease progressing, the pathology ascends, 
affecting other brain regions and promoting the appearance of other symptoms 
including the motor ones (6-9) (Fig. 1C). Supporting Braak’s concept, recent data 
suggests a “spreading”-like phenomena in PD. In particular it has been reported a 
time-dependent pathology appearance in normal mesencephalic grafts after being 
grafted in PD patients. The pathology included LBs and reduced dopamine 
transporter (10-14).  
Phenotypically several other diseases have fallen under the PD umbrella and are 
commonly denominated as PD-related disorders. Kufor-Rakeb syndrome (KRS) is 
one of these disorders. KRS patients display a similar clinical chart to severe PD 
cases with an early disease onset. Besides the common symptomatology, KRS 
patients also exhibit pallido-pyramidal degeneration and supranuclear upgaze 
paresis and are levodopa responsive (15). 
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Figure 1. An overview on PD: from patient to pathology. A) The typical posture of a 
PD patient was first illustrated by James Parkinson in his 1918 essay.  B) PD has two 
main pathological hallmarks: the degeneration of dopaminergic neurons at the SN and the 
presence of intracellular proteinaceous inclusions, known as LBs. C) Braak’s hypothesis 
for PD progression suggests that the symptomatic phase appears when the pathology is 
no longer confined to the brainstem and it ascends to other brain areas. Adapted from (2, 
16, 17). 
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1.1.1. PD Genetics 
 
The cellular triggers underlying PD remain as unknown as the disease progression 
itself. Only a minority of PD cases, less than 10%, have a defined genetic cause, 
with the majority of cases being reported as sporadic due to their unknown origin. 
Thus far alterations in approximately 20 genes have been associated with PD 
onset (18) (Table 1). The fact that these genes are involved in a broad spectrum of 
cellular processes, ranging from mitochondrial homeostasis to protein degradation 
machinery, reflects the complexity of PD pathophysiology. This fact is also a 
notorious obstacle to understand which alterations in proteins, pathways or 
organelles are the tipping point that promotes the disease onset and progression. 
Furthermore, several environmental factors such as metals, pesticides and 
insecticides are known to cause, or at least increase the risk of developing PD (19-
21). 
Despite the wide genetic variability, one protein stands out from the crowd and has 
been extensively studied in the last decades: alpha-Synuclein (α-Syn). Mutations 
in SNCA, encoding for α-Syn, were the first being associated with the disease, but 
also duplications and triplications of the gene were later found in PD patients. 
Besides its involvement in the familial forms of PD, the protein is commonly found 
in LBs (22) and LNs (23) in sporadic cases. 
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Table 1. PD associated genes 
AD	–	Autosomal	dominant;	AR	–	Autosomal	Recessive;	UR	–	Unknown	Relevance.	
	
Locus Protein Description Inheritance Reference 
PARK1/4 
Alpha-
Synuclein 
Presynaptic/ 
nuclear 
AD (24, 25) 
PARK2 Parkin Ubiquitin ligase AR (26) 
PARK3 SPR  AD (27) 
PARK5 UCH-L1 
Ubiquitin 
Protease 
AR (28) 
PARK6 PINK1 
Mitochondrial 
Kinase 
AR (29) 
PARK7 DJ-1 Several functions AR (30) 
PARK8 LRRK2 Kinase AD (31) 
PARK9 ATP13A2 P5 ATPase AR (32) 
PARK10 RNF11 (?) 
RING-finger 
Protein 11 
UR (33) 
PARK11 GIGYF2 
GRB10 
interacting GYF 
2 
AR (34) 
PARK12 IL-13Ra1 (?) Interleukin-13 UR (35) 
PARK13 Omi/HTRA2 Serine Protease UR (36) 
PARK14 PLA2G6 Phospholipase AR (37) 
PARK15 FBXO7 F-Box Protein AR (38) 
PARK16 (?) - UR (39) 
PARK17 VPS35 
Retromer 
Complex 
AD (40) 
PARK18 EIF4G1 
Translation 
Initiation Factor 
AD (41) 
PARK19 DNAJC6 HSP40 homolog AR (42) 
PARK20 SYNJ1 Synaptojanin 1 AR (43) 
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1.2. Alpha-Synuclein  	
1.2.1. Structure 	
Structurally speaking the 140 amino acids of α-Syn can be separated in three 
distinct domains: a N-terminus prone to mutations, a central domain necessary for 
aggregation and a C-terminus negatively charged (Fig. 2). Besides all the 6 
familial mutations (A30P, E46K, H50Q, G51D, A53E and A53T) that are found in 
the boundaries of the N-terminal domain (1 to 60), this region is also known for its 
several imperfect repeats of the consensus motif (KTKEGV) (24, 44-48). These 
repeats are responsible for the membrane binding and helix folding abilities to α-
Syn (49, 50) and they are also found in other proteins that display identical 
conformational alterations (51). Artificial mutations in this domain block the 
interaction with membranes and enhance the protein’s intracellular toxicity (52). 
The next 34 amino acids (61 to 95) form the central region, also known as non-Aβ 
component of plaque (NAC) domain, and represent the main structural difference 
between the three members of the synuclein family. Highly hydrophobic, this 
region contains 12 amino acids (71 to 82) essential for α-Syn filament formation 
(53). The C-terminal part of α-Syn that includes 44 amino acids is rich in 
glutamates and aspartates imparting a negative charge to the protein. These 
negative residues can modulate α-Syn aggregation propensity (54) and, according 
to some reports, this domain may be responsible for the protein’s chaperone-like 
activity (55). 
Classically, α-Syn has been considered an unfolded monomeric protein. In 2011, 
two reports brought controversy to the field by suggesting a native α-Syn 
tetrameric conformation enriched in alpha-helical structure (56, 57). These findings 
where rapidly questioned by other groups who found evidence for a predominance 
of the protein in monomeric and disordered state (58, 59). Nevertheless, this year 
the tetramer hypothesis was again highlighted with two novel papers reaffirming 
the presence of α-Syn tetrameric in physiological conditions (60, 61). These two 
reports put the KTKEGV imperfect repeats as the key mediator of α-Syn 
tetramerization and describe how some of the familial mutations can shift the 
equilibrium from tetramer to monomer leading to an increase in cellular toxicity. 
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α-Syn is highly susceptible to several post-translational modifications (PTMs), 
which seem to modulate the protein's propensity to aggregate, as well as its 
cellular behaviour and fate. The protein can be phosphorylated at two serines 
(S129 and S87) and three tyrosines (Y125, Y133 and Y135). Phosphorylation at 
S129 is considered a biochemical marker of LBs since approximately 90% of α-
Syn present in LBs is phosphorylated in this residue (62, 63). Several kinases 
including Casein Kinases, Polo-Like Kinases and G protein-clouples receptor 
Kinases can phosphorylate α-Syn at position 129 (62, 64-68) with some of those 
enzymes being found up-regulated in PD brains (67), or present in LBs (65, 69). 
The S129 phosphorylation is described to affect α-Syn fibrillation although it is still 
unclear if this specific PTM enhances or inhibits this cellular process (63, 70-72). 
As for the phosphorylation at position 87 an inhibitory effect on aggregation has 
been observed (73). Less is known regarding phosphorylation of the tyrosines 
residues although, in flies, it has been described that Y125 phosphorylation leads 
to a decrease of α-Syn oligomeric species. Unfortunately, the full functional 
relevance of α-Syn phosphorylation both in a physiological and disease context is 
still unknown (74, 75).  
In addition to phosphorylation, tyrosine residues (Y39, Y125, Y133, Y136) can also 
be nitrated, a PTM known to increase α-Syn toxicity. Nitrated α-Syn was found in 
LBs (76) and nitrated oligomers promoted mitochondrial impairment and cell death 
in mammalian cells (77). Substantial loss of dopaminergic neurons at the SN, 
accompanied by down-regulation of striatal dopamine and dopamine receptor D2, 
was observed upon injection of nitrated α-Syn into SN of rats (78). Interestingly 
nitration of position Y39 can inhibit α-Syn fibril assembly and reduce monomer 
degradation via the ubiquitin proteasome system (79).  
Truncated α-Syn has also been found in LBs and animal models, with findings 
suggesting that familial mutations can increase its occurrence (80-82). In vitro 
truncation of α-Syn at the C-Terminus can enhance fibril formation and promote 
the fibrilization of full-length α-Syn (83, 84). Nevertheless the opposite effect was 
reported upon calpain 1- or neurosin-mediated α-Syn truncation (85-88). These 
two proteases cleave α-Syn near the NAC domain highlighting the importance of 
this region in α-Syn aggregation. 
α-Syn can also undergo other PTMs including ubiquitination (82, 89-91), 
sumoylation (92-94) and acetylation (95-97). Ubiquitinaton occurs mainly at the N-
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terminus of α-Syn protein sequence (98) although it has been described that 
important Ubiquitin ligases require α-Syn C-terminus to proper modify the protein 
(99). Ubiquitinated α-Syn can be found in LBs and this PTM can affect the 
protein’s degradation via de endolysosomal and autophagy pathways (89, 99, 
100). Identical to ubiquitination, sumoylation also targets lysines and, in regards to 
α-Syn, the lysines 96 and 102 are the main amino acids affected by this PTM (92). 
The presence of sumoylated α-Syn has been descibred in aggregates of α-Syn 
although it is believe that this PTM can inhibit the aggregation formation (92, 93). 
A recent report presented a more functional role for α-Syn sumoylation describing 
an important role of this PTM on the protein’s secretion by exosomes (101). 
Lastly, N-terminus acetylation of α-Syn has been has been repetitively associated 
to the protein’s capability for membrane binding and this PTM was also described 
to increase α-Syn resistance to aggregation (95-97). 
 
 
1.2.2. Function 	
α-Syn was initially described in 1988 and its name derives from its intracellular 
localization: Syn- from synapse and -nuclein from nucleus (102).  More than a 
quarter of a century later, the scientific community has yet to reach a consensus 
regarding the intracellular function of α-Syn. Several reports have so far have 
suggested a wide spectrum of hypothetical roles ranging from neurotransmitter 
release, to DNA binding, and mitochondrial homeostasis (103-105). The strongest 
evidence points towards a pre-synaptic function. Supporting this line of evidence is 
the protein’s abundance in the brain (106) as well as the described pre-synaptic 
localization (102, 107) and its co-localization with the reserve pool of synaptic 
vesicles (108, 109). Initial reports suggested that α-Syn could play several roles in 
the cycling of synaptic vesicles, modulating the vesicle pool size, mobilization and 
endocytosis (110, 111). Accordingly, altered synaptic vesicles dynamics, along 
with decreased striatal dopamine, are the minor alterations described in α-Syn 
knockout (KO) mice (112, 113). Notorious concerns regarding potential 
compensatory mechanisms, generated by other members of the synuclein family 
(b and g), led to the generation of double and triple KO animals. In KO mice for α-
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Syn and b-Syn no alterations in synaptic vesicle dynamics were observed, though 
the animals exhibited alterations in pre-synaptic protein levels together with a 
distinct decrease of dopamine levels throughout the brain (114). Likewise the 
triple-synuclein KO mice also showed changes in the levels of pre-synaptic 
proteins and a more severe phenotype, including decrease of synaptic terminal 
size and higher lethality (115).  
Important work developed by Südhof and colleagues suggests that α-Syn interacts 
with synaptobrevin-2 (VAMP2) and with phospholipids via its C- and N-termini, 
respectively (116). This interaction promotes Soluble NSF Attachment Protein 
Receptor (SNARE) complex assembly and recent data indicates that α-Syn 
multimerization ability is required upon binding to membranes (116-118). The role 
of α-Syn might be extremely specific since this interplay was only reported in 
docked membranes at the plasma membrane (117) (Fig. 2). Nevertheless VAMP2 
has been linked to other intracellular pathways besides neurotransmitter release 
so it is possible that α-Syn has a broader role in the intracellular trafficking 
mechanisms (119, 120). Supporting this idea is the fact that both α-Syn and 
VAMP2 and strongly present in erythrocytes, blood cells that do not perform 
synaptic vesicles transmission (56, 121).  
Nevertheless, reinforcing a putative function of α-Syn on synaptic homeostasis, 
the protein was also shown to compensate the loss of the pre-synaptic cysteine-
string protein-alpha (CSPα) in mice. CSPα KO animals display impairment of 
SNARE assembly, followed by pronounced neurodegeneration and early lethality. 
Overexpression of α-Syn in these mice was able to partially rescue the phenotype 
and increase their life expectancy with the authors suggesting that α-Syn could 
enhance SNARE-complex assembly acting downstream of CSPα. Additionally KO 
animals for both α-Syn and CSPα present the most severe phenotype, confirming 
the involvement of α-Syn in the compensatory mechanism (122, 123).  
1.2.3. Toxicity and Disease 
 
Despite many open questions regarding the physiological function of α-Syn, this 
14.5 kDa protein has taken a central stage in research on neurodegeneration due 
to its involvement in several brain-related diseases, commonly described as 
synucleinopathies. PD is one of these disorders and, as mentioned above, α-Syn 
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is considered an important component of the LBs and LNs although the positive or 
negative cellular effect of these inclusions is still elusive. A total of 6 mutations in 
its 140 amino acids have been found in PD patients and duplication or triplication 
of the SNCA gene lead to the same clinical phenotype (24, 25, 44-48, 124). 
Recent studies also revealed that polymorphisms in the SNCA gene lead to an 
increase of PD risk (39, 125-127).  
In addition to PD, the group of synucleinopathies is composed of three other 
neurological disorders: Multiple Systems Atrophy (MSA), Dementia with Lewy 
Bodies (DLB) and Pure Autonomic Failure (PAF). Of the three, MSA is the 
disorder with a strongest connection to α-Syn, although in terms of pathology is 
the more distinct one. MSA patients present proteinaceous inclusions in 
oligodendrocytes (128-130). Two recently described mutations in α-Syn (A53E 
and H50Q) were found in patients displaying MSA pathology, and polymorphisms 
in the α-Syn gene can also enhance the risk for disease onset (48, 131-133). 
Patients with DLB exhibit dementia and other Alzheimer-like symptoms due to a 
stronger pathological effect in the cortex area (134). The clinical discrimination 
between PD and DLB is challenging since almost half of all PD patients also 
develop dementia as the disease progresses (135). More distinct from the other 
disorders is PAF. This disease affects the peripheral nervous system and also 
presents α-Syn-positive LBs and LNs, although some researchers postulate that 
PAF in no more than an intermediate disease state that later progresses into other 
neurological disorders (136-138).  
The origin of α-Syn toxicity is still a debatable subject but its deleterious effects 
have been associated to the majority of the intracellular organelles and pathways. 
In fact it has been described that α-Syn can impair vesicle and protein trafficking, 
protein degradation systems, mitochondrial respiration, microtubule polymerization 
and neurite network (139-145). As mentioned above, the structure of α-Syn 
confers its aggregation propensity. Thus, understanding the mechanisms 
underlying this process has become the central quest in the field of 
synucleinopathies. Three main α-Syn species are commonly represented in the 
“aggregation pathway” that start with monomers, followed by the formation of 
intermediate oligomers, and finalized with aggregates/inclusions (Fig. 2). Once 
again a clear lack of consensus exists regarding the toxic elements of this pathway 
with some evidence pointing towards the oligomers (146-148), while other suggest 
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the aggregates (149, 150) (Fig. 2). Knowing that LBs are found in surviving 
dopaminergic neurons, it has been speculated that they may represent a pro-
survival response to the cellular toxicity. Nevertheless a recent work concluded 
that different α-Syn assemblies could lead to distinct but yet complementary 
molecular and behavioural patterns (151). These data suggest that more than one 
culprit species could be underlying the disease onset. 
Additionally, since the function of α-Syn might require a multimerization process 
upon membrane binding, it is likely that the protein is constantly shifting between 
cytosolic monomer and membrane-bound multimer. It has now become essential 
to chemically, structurally and biologically distinguish between “functional 
oligomer” and “toxic oligomer”. Altogether this data points to an extremely 
sensitive cellular balance between of function and dysfunction that weight towards 
one of them according to the protein propensity to bind membranes. 
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Figure 2. α-Syn: structure, function and toxicity. α-Syn is an intrinsically disordered 
protein with 6 PD-related point mutations described so far. The protein can undergo 
oligomerization/multimerization that, under pathological conditions, can lead to the 
formation of beta-sheet structured aggregates. The outcome of the oligomerization can 
determine the existence of a functional (blue) or dysfunctional (grey) α-Syn with recent 
data suggesting a crucial role for the protein's membrane binding domains in this process. 
In terms of function, α-Syn has been strongly associated with vesicular trafficking, and 
particularly with synaptic vesicles, interacting with important players in this pathway. 
Although it is still not fully understood which α-Syn species are toxic, putative deleterious 
effects on several intracellular organelles and pathways, including proteasomes, 
lysosomes, synapses, microtubules, ER-to-Golgi trafficking and membranes, have been 
described (152). 			
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1.3. ATP13A2 	
1.3.1 Structure 
 
ATP13A2, also known as Park9, is a transmembrane protein of 1180 amino acids 
that mainly localizes in lysosomes and late endosomes (32). The protein is a 
member of the P5 type pump ATPases family, together with 4 other proteins, 
ATP13A1 and ATP13A3-5. Bioinformatic analyses suggest that ATP13A2 has 11 
transmembrane domains and four functional domains: an actuator domain (A), a 
catalytic phosphorylation site (P1), and two nucleotide-binding domains (P2 and N) 
(153) (Fig. 3A). The protein is highly expressed in the brain, particularly in the SN 
and is upregulated in the dopaminergic neurons of this region in the brains of PD 
patients (32, 154). A recent work provided new insights about the intracellular 
behaviour and homeostasis of ATP13A2. Both C- and N-terminus of the protein 
are faced towards the cytosol with the latter terminal having a unique conformation 
that is provided by the eleventh transmembrane domain (155). Additionally it was 
observed that ATP13A2 could be autophosphorylated in its inactive state with 
several phosphates being able to induce this process also via the N-terminus 
(155).  
 
1.3.2. Function 	
The cellular function of ATP13A2 is still elusive, as in the case of α-Syn. 
Fibroblasts obtained from patients with ATP13A2 mutations, revealed profound 
alterations in mitochondrial homeostasis. This impairment was associated with 
reduced ATP production and increased maximum respiration capacity, due to an 
impairment of mitochondrial degradation and subsequent accumulation of 
defective organelles. These phenotypes could be partially rescued upon ATP13A2 
overexpression (156). The process of autophagic mitochondria degradation, 
known as mitophagy, is a crucial quality control mechanism to ensure the proper 
function of the organelle (157). An imbalance in this process has been associated 
with PD (158).  
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ATP13A2 has been directly linked to mitophagy in several studies (156, 159, 160) 
but little is known about which mechanisms are involved (Fig. 3C).  
Apart from mitophagy ATP13A2 has been connected with normal protein 
autophagy (161-163) and metal/cation homeostasis (154, 160, 163-172) (Fig. 3C). 
Regarding the latter, ATP13A2 was shown to have a protective effect in 
manganese (Mn+)-mediated α-Syn toxicity, in both yeast and SH-SY5Y cells (166) 
(Fig. 3C and D). This role in Mn+ homeostasis was further explored in yeast and 
allowed the identification of several genes involved in the process (168). 
Furthermore some ATP13A2 mutants were unable to rescue Mn+ induced toxicity 
in mammalian cells (170) and two ATP13A2 polymorphisms enhance Mn+ 
neurotoxic effect in patients (169). Considering that this metal has been linked to 
Parkinsonism (173), and specifically to α-Syn oligomerization and aggregation 
(174, 175), one can speculate that Mn+ could be an intermediate between α-Syn 
and ATP13A2. This hypothesis is not fully accepted since a recent report 
concluded that in mammalian cells, ATP13A2 levels had no effect on Mn+ 
sensitivity (164).  
Besides Mn+, ATP13A2 was shown to exert a protective effect against niquel- 
(Ni2+), cadmium- (Cd2+) and selenium- (Se2+) induced toxicity, in yeast and in 
mammalian cell culture (171, 172), yet little is known about the role of these 
metals in the context of α-Syn toxicity and PD.  
More recently, ATP13A2 was also linked to zinc (Zn2+) homeostasis in a study 
showing that mitochondrial impairment, due to increased amounts of Zn2+, could 
be rescued upon overexpression of ATP13A2 (160). The interplay between α-Syn, 
ATP13A2 and Zn2+ has been strongly associated with autophagy and extracellular 
release and it will be further developed ahead. 
The first results with ATP13A2 KO mice showed that the animals exhibit both PD 
and NCL pathology, including the formation of intracellular aggregates positive for 
α-Syn and ubiquitin, sensorimotor deficits and lipofuscinosis (161), suggesting that 
the phenotypes may not be solely gene dependent. A recent report further 
indicated that, in these mice, α-Syn accumulation was a side effect from a general 
impairment of the endolysosomal pathway (176).  
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1.3.3 Toxicity and Disease 
 
Mutations in ATP13A2 have been associated with different diseases including PD, 
KRS (32, 177-185), and also Neuroid Ceroid Lipofuscinosis (NCL) (186-188).  Of 
the several disease-associated mutations identified in ATP13A2, thus far only a 
few were investigated in detail. In cells ATP13A2 mutants exhibited loss of protein 
function, subcellular mislocalization in the endoplasmic reticulum (ER), increased 
cellular toxicity, and shorter protein half-life (Fig. 3D) (189). In a detailed study of 
the effects of ATP13A2 missense mutations associated with early-onset 
parkinsonism several novel phenotypes were identified, including disruption of the 
protein vesicular localization, impairment of ATPase activity and of neurite 
outgrowth (190). One of these mutations, commonly known as Dup22, was initially 
described in a Jordanian family. The patients (four in total) exhibited an early age 
of onset (12-15 year old) with rapid disease progression. Cardinal PD symptoms 
like rigidity, bradykinesia and postural instability were present, accompanied by 
non-motor symptoms such as hallucinations. Genetically the Dup22 mutation 
consists in a duplication of 22 base pairs (1632-1653) that promotes the formation 
of 236 erroneous amino acids followed by a stop codon. At a structural level, this 
mutated protein lacks 6 of the 10 transmembrane domains of ATP13A2 (Fig. 3B) 
(32, 191, 192). Despite the believe that the lost of transmembrane domains could 
lead an intrinsic incapability of ATP13A2 to be targeted to its final destination, a 
recent study revealed that the presence of N-terminus is enough for the protein’s 
colocalization at the late endosomes and lysosomes (155). 
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Figure 3. ATP13A2 structure and hypothetic role in physiological and pathological 
conditions. A) ATP13A2 is an 1180 amino acids protein with 10 transmembrane domains 
and four functional domains: catalytic phosphorylation (P1), nucleotide binding (P2 and N) 
and actuator domain. B) The familial mutation Dup22 removes 6 of the transmembrane 
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domains that constitute the ATP13A2 WT C) ATP13A2 is thought to play a role on metal 
homeostasis and autophagy process, including protein and mitochondrial degradation via 
the lysosome. D) A failure in metal processing, caused by mutations or reduced activity of 
ATP13A2, would lead to the toxic accumulation of metals in the cytoplasm.  In disease 
conditions, α-Syn may increase the intracellular levels of metals, exacerbating cytotoxic 
effects. Regarding protein and mitochondria degradation it has been reported that 
deficient ATP13A2 activity can lead to the accumulation of defective mitochondria or 
proteins (such as α-Syn) that ultimately contribute to increased cytotoxicity. Adapter from 
(193). 
 
1.4. Protein Degradation 
 
The correct degradation of proteins is an important process to assure the proper 
intracellular homeostasis and it is ensured by two independent, but 
complementary, systems. These two mechanisms, the autopaghy-lysosomal 
pathway and the Ubiquitin Proteasome System are named upon their final 
destination organelle, the lysosome and the proteasome, respectively. Monomeric 
α-Syn can be actively degraded by both organelles (194, 195) that can 
compensate each other upon one’s failure (196). When it comes to eliminating 
higher molecular species the lysosome is the only organelle able to deal with them 
and promote their correct degradation (197). Considering that both ATP13A2 and 
α-Syn have been extensively linked to the lysosome, I will further develop the 
pathways associated with this organelle.  
 
1.4.1. The lysosome 
 
Cell survival requires the constant turnover of its functional machinery, such as 
proteins and organelles, and the lysosome constitutes the main cellular 
component responsible for this task. This turnover is crucial for the removal of 
deleterious intracellular components, and for the recycling of macromolecules to 
guarantee proteome renewal (198). Autophagy (meaning “self-eating”, in Greek) 
consists in the process of decomposition and degradation of cellular components 
and organelles via the lysosomal compartment. Autophagy itself serves two main 
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purposes: the clearance of deleterious intracellular components, and the recycling 
of macromolecules from functional pre-existing organelles and proteins to 
guarantee proteome renewal (198). 
When it comes to protein and organelle degradation, the lysosome can be the end 
point of several pathways that can be categorized in two different groups: the 
autophagy pathway and the Endolysosomal pathway. The first group can be 
divided in three pathways based on the cargo delivery method: chaperone-
mediated autophagy (CMA), macroautophagy and microautophagy. The 
Endolysosomal pathways, despite also culminating in the lysosome, display 
distinct molecular players and can have two distinct origins: the ER or endocytic 
mechanisms. 
For the purpose of this thesis, I will focus on macroautophagy and the 
endolysosomal pathways. 
 
 
1.4.1.1. Macroautophagy 
 
Macroautophagy is a bulk, content-blind, cellular degradation mechanism that 
requires the formation of de novo double membrane-bound vesicles to sequester 
intracellular components, including whole organelles, towards the lysosome (199, 
200). The entire mechanism deeply relies on the so-called autophagy-related 
proteins (Atg) that were first described in yeast (201-203). In fact, the formation of 
the de novo membranes mainly depends on the autophagy related protein (Atg) 9, 
both in yeast and humans (204-207). Macroautophagy is found constitutively 
active but it can be enhance either via the mTOR pathway, the mammalian target 
of rapamycin (208), or via the PI3kinase/beclin/vsp34 pathway (209). The 
autophagosome formation requires two ubiquitination steps highly regulated by 
Atg proteins (201-203). Initially Atg12 is conjugated with Atg5, a process involving 
Atg7 and Atg10 (210, 211). The Atg12-Atg5 complex is later targeted to the 
autophagosome together with Atg16 (212, 213). The localization of this complex at 
the membrane is required for the second ubiquination step to occur, via Atg8 (also 
known by LC3) (214, 215). LC3 is C-terminally cleaved by Atg4 to form LC3-I (216, 
217), which is then conjugated to the lipid phosphatidylethanolamine (PE) by Atg7 
and Atg3 to generate LC3-II (211, 218). LC3-II is the most common marker for 
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autophagy since it is specific to this pathway and degraded only after the fusion of 
the autophagosome to the lysosome (217). After formation, the autophagosomes 
travel along the microtubules in a dynein-dependent manner towards the 
microtubule organizing centers where the lysosomes are located (219) (Fig. 4A). 
The release of the autophagosome content to the lysosome can be performed 
either by fusion of both compartments or just by a transfer of the autophagosome 
content to the lysosome without loss of the first structure (219). The mechanisms 
underlying the fusion of both compartments are largely unknown in mammalian 
cells, except for the fact that Rab7 plays a role on this process (220). 
 
1.4.1.2. The Endolysosomal Pathway 
 
The endosomal pathway is a complex intracellular trafficking mechanism that has 
been extensively associated to PD (221). In this pathway the early endosomes 
(EE) are the main sorting pit stops that receive content originating in the plasma 
membrane via endocytosis, and from the Trans-Golgi network (TGN). Once inside 
the EE the content may have two destinations: either it is targeted to the lysosome 
to be degraded or it is recycled towards the plasma membrane. Depending on 
their faith, the proteins are usually found in different sections of the EE. 
Specifically, proteins that will be recycled are commonly found in the tubular 
sorting endosome while the ones targeted for the lysosomes are present in the 
vacuolar sorting endosome. In the latter the content is stored in intraluminal 
vesicles (ILV) that originate by inward budding of the EE membrane. The content 
of the ILVs and their formation is strongly dependent on the endosomal sorting 
complexes required for transport (ESCRT) (222-224). The cargo identification by 
the ESCRT typically demands a previous ubiquitination step, although an ESCRT-
independent mechanism has also been described (222, 225). The vacuolar 
endosome suffers a process of continuous maturation that culminates in the 
formation of late endosome (LE), via multivesicular Bodies (MVBs). At this stage 
the LE contains few proteins intended for recycling after endocytosis, and the 
majority of the content being targeted for the lysosome. Importantly, differences 
are also observed in the protein composition at the membrane of the LE with the 
most well described alteration being a Rab conversion, consisting in a switch 
between Rab5, present in the EE, and Rab7 found in LE (226). A second sorting 
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event takes place at the LE/MVBs complex, enabling the content can either be 
forwarded towards the lysosome for degradation or targeted to the extracellular 
environment via exosomes (Fig. 4B). The biological function of exosomes is still 
elusive, but some speculate that these vesicles may constitute a cellular clearance 
route to proteins that cannot be degraded by the lysosome (227). 
Besides the notorious role in protein degradation, the endolysosomal pathway 
itself is of an extreme importance for the lysosome biogenesis and function. It is 
through this pathway that lysosome membrane proteins and intralysosomal 
hydrolases are delivered to the lysosome. The most studied pathway is the M6PR-
dependent transport, used by proteins such as Cathepsin D (CatD), and relies on 
the addition of an M6P-tag to the hydrolases, though some proteins can undergo 
different processing (228, 229). Regarding M6P-independent pathways, recent 
findings point that hydrolases can migrate to the lysosomes bounded to lysosomal 
membranes, like β-Gluocerebrosidase, a protein which gene, GBA, has been 
extensively linked to PD (230, 231). 
The extensive network of the endosomal pathway requires the constant movement 
of the vesicles inside the cell. Rab proteins are major regulators of the dynamics 
underlying these movements, and the overall intracellular trafficking (232, 233). 
More than 60 members compose the highly conserved Rab family (234) with 
Rab5, Rab7 and Rab22B being the ones more linked to this endosomal 
mechanism (235) (Fig. 4B). Nevertheless Rab8a, which has been previously 
linked to α-Syn (236), has recently emerged as an important protein in the normal 
function of this pathway (237). In detail, it was shown that normal endolysosomal 
requires the presence of the complex Rab8 and optineurin at the Golgi membrane 
(237). A mislocalization of the complex leads to decrease in CatD maturation and 
impaired lysosomal protein degradation. 
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Figure 4. Mechanisms of protein degradation: autophagy and endolysosomal 
pathways. A) Three main cellular pathways can enhance macroautophagy: mTor 
dependent, mTor independent and JNK/Blc2. All terminate in the complex Beclin-1/VPS34 
that will promote the formation of the autophagosome that surrounds the content targeted 
to degradation. This autophagosome formation starts with an ubiquitination reaction where 
Atg12 is conjugated to Atg5, a process mediated by Atg7 and Atg10. After the binding of 
Atg16L, the Atg12/Atg5/Atg16L complex is targeted to the autophagosome. This complex 
localization at the membrane is necessary for the second ubiquination and requires LC3. 
Initially, LC3 is cleaved at the C-terminus by Atg4 to form LC3-I, which is then conjugated 
to a PE by Atg7 and Atg3 to generate LC3-II. The membrane of the autophagosome is 
originated from other organelles and transported by Atg9. After closing the 
autophagosomes is moved towards the lysosomes where it fuses, to deliver the cargo for 
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degradation. B) The endolysosomal machinery involves several intracellular players. The 
content being delivered into the lysosome can arise from the TGN, where Rab8a is a 
master player, or through the extracellular environment via endosomes that are positive 
for Rab11. In either case, the content is targeted to the Vacuolar Sorting component of the 
EE. This structure will then give origin to the LE/MVBs a process that requires a Rab 
conversion from Rab5 to Rab7 at the membrane level. These LE/MVBs that can undergo 
two distinct pathways: 1) form Rab27a positive exosomes and release the content to the 
extracellular media or 2) fuse with the lysosomes to allow the degradation of proteins or 
the delivery of lysosomal membrane proteins and hydrolases. Adapted from (238). 
 
1.4.2. The interplay between α-Syn, ATP13A2, and protein degradation 
pathways 
 
Monomeric α-Syn degradation is divided into two complementary mechanisms, the 
ubiquitin proteasome system and the CMA (194, 195) that compensate each other 
upon one’s failure (196). When it comes to eliminating higher molecular species 
the burden shifts entirely to the lysosome (197). Nevertheless, the CMA cannot 
handle species larger than dimers (239, 240) so another mechanism, 
macroautophagy, is activated. 
The degradation of α-Syn via macroautophagy has been mostly studied by using 
specific inhibitors and enhancers of this pathway. Macroautophagy can degrade 
both WT and mutant α-Syn in a Beclin-1 dependent process (99, 241, 242), 
though some literature points to a mutant-specific degradation (243, 244). 
Formation of high molecular weight species has been reported upon blockage of 
this pathway, although the results are controversial (245, 246). No overall 
consensus has been reached on the effect of macroautophagy in α-Syn 
homeostasis, although in yeast, a model organism that lacks CMA, it was 
demonstrated that phosphorylation and sumoylation of α-Syn are able to modulate 
the protein’s degradation via this pathway and, ultimately, inclusion formation (71, 
94).  
On the other hand, α-Syn also impacts macroautophagy. The overexpression of 
the protein can inhibit macroautophagy via an interaction with Rab1a that 
culminates in a mislocalization of Atg9 (141). In DLB patients and αSyn 
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overexpressing transgenic mice an increase in mTor and decrease in Atg7 levels 
has been observed (140) (Fig. 5A). The same study also reported the presence of 
enlarged autophagosomes and lysosomes, as it was first observed in cells 
overexpressing α-Syn (241).  A recent work reported a drastic effect in the 
presence of α-Syn aggregates, as these species appear to be resistant to 
macroautophagy and promote a general failure of the pathway with subsequent 
accumulation of autophagosomes (150) (Fig. 5D). Besides the WT α-Syn, also the 
familial PD-associated mutations can have a deleterious effect on 
macroautophagy. The familial mutation E46K was reported to impair 
macroautophagy via inactivation of the JNK1/Blc2 pathway (247) (Fig. 5B). As for 
the A53T mutation opposite effects were described, with one group suggesting an 
enhancement of macroautophagy, especially the mitophagy pathway (248), while 
other suggested an impairment of degradation leading to the accumulation of 
autophagosomes (249) (Fig. 5C). 
 
 
Figure 5. The interplay between α-Syn and macroautophagy. A) Accumulation of α-
Syn can increase mTor, decrease Atg7 levels and promote mislocalization of Atg9 that, 
individually or combined, can alter the delicate homeostasis of macroautophagy.  B) α-
Syn familial mutation E46K was described to inhibit macroautophagy via JNK/Blc2, an 
	 	 		
	 24	
mTor independent pathway. C) On the other hand, two opposite effects have been 
associated with the A53T mutation: increase in mitophagy, and accumulation of 
autophagosomes due to impaired degradation. D) As for α-Syn aggregates, these species 
cannot be degraded by macroautophagy, leading to the impairment of the pathway. 
Adapted from (238). 
 
Once inside the lysosome, α-Syn degradation is a task usually performed by CatD 
(250). Synthetized in the ER, this protease is initially cleaved generating an 
inactive proCatD (251). The proCatD is then targeted to the lysosome, a process 
that was found to be endosome-mediated (252, 253). Upon reaching an acidic 
environment, cysteine proteases are responsible for the cleavage of proCatD at 
the N-terminus to originate the active form of CatD (254, 255). Confirming the 
relevance of CatD in α-Syn homeostasis, overexpression of CatD was shown to 
protect against α-Syn-induced toxicity (256). CatD KO mice exhibit the formation 
of insoluble α-Syn species while in cell models the expression of an inactive 
mutant of CatD generated identical effects (257, 258). Increased levels of mutated 
CatD enhanced the expression of Cathepsin B, a protease that can promote α-Syn 
aggregate formation (256, 259). Recent findings indicate that treating cells with α-
Syn aggregates leads to lysosomal rupture and cathepsin B dependent ROS 
production (260). At the pathological level, decrease of CatD has been described 
in neurons of the SN with α-Syn-positive aggregates, in PD patients (261). 
Nevertheless other groups reported no difference in CatD between PD patients 
and controls (262, 263).  
As mentioned above, ATP13A2 has been strongly associated with autophagy, 
mainly due to its localization at the LE and lysosomes membranes. ATP13A2 
knockdown (KD) and KO models exhibit an impairment of α-Syn degradation (161, 
162). Further results pointed towards an overall autophagy impairment due to 
alterations of lysosomal pH and the levels of hydrolases leading to a failure in 
autophagosomes clearance, and a decreased proteolytic processing (162, 163, 
165). Recently, it was suggested that aggregate formation in ATP13A2 KO mice 
was α-Syn-independent, and a clear impairment of the endolysosomal pathway 
was reported. This impairment resulted in a reduction in CatD maturation, and 
localization at the lysosome (176). These findings are in agreement with a 
previous report showing a decrease in CatD activity upon ATP13A2 mutations in 
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Medaka fish (264), and puts both CatD and ATP13A under the spotlight. Curiously 
mutations in both CatD and ATP13A have been associated to NCL and, alike 
ATP13A2, CatD KO mice exhibit a NCL phenotype, which may suggest that 
similar cellular mechanisms are taking place (161, 186, 265, 266) (Fig. 6A and B).  
Another strong line of research combines protein clearance with metal 
homeostasis in the paradigm correlating ATP13A2 and α-Syn. Two recent studies 
suggest unbalanced Zn2+ homeostasis as the starting point of a chain of events 
responsible for α-Syn clearance. The first study showed that alterations in Zn2+ 
intracellular levels and cellular sub-localization could promote lysosomal 
dysfunction and α-Syn accumulation. This phenotype was enhanced upon 
ATP13A2 KD, in cells and in fibroblasts from patients carrying ATP13A2 
mutations, and could be rescued after ATP13A2 overexpression (165). On the 
other hand, an independent study focused upstream of the endolysosomal 
pathway, in particularly the LE/MVBs. The authors found that MVBs are targeted 
to exocytosis, instead of autophagy, and this mechanism is the main pathway 
underlying the decrease of intracellular α-Syn levels (164). In this perspective, 
ATP13A2 was shown to modulate Zn2+ levels, which, in turn, could influence the 
biogenesis of exosomes (Fig. 6A and B). 
Altogether, it becomes obvious that the endolysosomal pathway, either due to 
metal homeostasis or protein degradation imbalance, plays an important role in 
neurodegeneration and, more specifically, in PD. 
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Figure 6. The hypothetical interplay between ATP13A2, Zn2+ and α-Syn. A) In normal 
conditions CatD is processed via the TGN and delivered to the lysosome via the 
endosomal pathway. Importantly ATP13A2 appears to play an important role in the 
maturation of CatD. ATP13A2, together with Zn2+, appear to regulate the intracellular fate 
of α-Syn towards either the lysosome or the extracellular medium via exosomes. B) 
Mutations in ATP13A2 or the absence of the protein can inhibit the maturation of CatD 
and its localization at the lysosome. In ATP13A2 KO mice the formation of aggregates 
positive for α-Syn has been described, an identical situation reported in CatD KO mice. In 
cell models mutations or KD of ATP13A2 promoted the release of α-Syn to the 
extracellular medium in a process that involved Zn2+ homeostasis. 
 
 
1.5. Endoplasmic Reticulum Homeostasis 	
To ensure proper protein function, macromolecules need to undergo a meticulous 
process of synthesis and folding. The ER is one of the main organelles involved in 
this process, and is also an important fall-back player upon proteostasis 
impairment. 
After production in the cytosol, two main protein types go through ER processing: 
water-soluble and transmembrane proteins, like ATP13A2. The ER also has a role 
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in the synthesis of lipids, that will be integrated in the majority of cell organelles 
such as mitochondria, lysosomes, peroxisomes, Golgi and even the plasma 
membrane (267). As previously mentioned, the ER also provides de-novo 
membranes to the autophagosome, via Atg 9, and is essential in macrosecretion 
(268, 269). 
The accumulation of misfolded, mutated or aggregated proteins at the ER lumen 
triggers an organelle response, commonly referred to as ER stress, and the 
activation of a cascade of cellular pathways, known as Unfolded Protein Response 
(UPR). Depending on the amount of accumulated misprocessed proteins, and the 
duration of the stress, two opposite pathways can be activated. More specifically, 
under transitory stress, pro-survival pathways are initiated but upon prolonged 
stress, apoptotic cell death mechanisms assume control. Both cellular faiths rely in 
common initiators that lay on the ER membrane: the inositol-requiring enzyme 1 
alpha (IRE1alpha), the protein kinase RNA-like ER kinase (PERK) and the 
activating transcription factor 6 (ATF6) (270-273). Under resolvable ER stress, the 
three cascades work in symbiosis by activating or inhibiting several pathways to 
promote cell survival. Briefly upon phosphorylation, PERK activates its 
downstream target eiF2a (eukaryotic translation initiation factor 2a), leading to the 
inhibition of new protein translation mechanisms and activation of an antioxidant, 
autophagy response (273, 274).  
The IRE1alpha pathway is based on an unconventional splicing of the X-Box 
binding protein 1 (XBP1) that will actively promote the transcription of genes 
involved in protein folding, autophagy and ER-associated protein degradation 
(ERAD) (275, 276). IRE1alpha can also upregulate the Regulated IRE1-alpha-
Depdendent Decay (RIDD) pathway that is responsible for mRNA degradation. 
Recent data suggests that RIDD action is crucial to maintaining the Death 
Receptor 5 (DR5) mRNA levels reduced and avoid the activation of caspase 
pathways. As for ATF6 the cytosolic fragment generated upon its cleavage will 
translocate to the nucleus and enhance the transcription of chaperones and ERAD 
associated genes (277). This latter cascade is the only of the three that is not 
active in the apoptotic and cell death signalling. 
Prolonged (chronic) ER stress leads to an alternative, pro-apoptotic cascade. The 
majority of ER-mediated death signalling originates from the PERK pathway that, 
via ATF4, promotes the stable upregulation of the C/EBP-homologous protein 
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(CHOP) (274), a master player in ER stress. This protein will then upregulate DNA 
damage-inducible 34 protein (GADD34) inhibiting the pro-survival Bcl2 and 
upregulating pro-apoptotic Bax, which culminates in increased ROS production 
and activation of the caspase cascade (278, 279). Another player, which is 
common to both PERK and IRE1alpha pathways, is Nuclear Factor kappa B (NF-
κB) that is activated either via eiF2a or TRAF2 (TNF receptor-associated factor 2), 
respectively (280-282). The latter protein can also activate the Apoptosis Signal-
regulating Kinase 1 (ASK1) that ultimately leads to JUN amino-terminal Kinase 
(JNK) and caspase activation (283-285). 
Activation of pro-survival versus apoptotic pathways requests a fine-tuned 
machinery and signalling. A recent work provided a deeper understanding on the 
mechanisms underlying the molecular shift between short-term and chronic ER 
stress (286). Under resolvable stress a survival cascade mediated by IRE1alpha 
compensates the pro-apoptotic cascade, initiated by PERK, that ultimately lowers 
DR5 mRNA levels. Nevertheless, in case of unmitigated stress the IRE1alpha 
pathway is somehow attenuated and the PERK cascade, via CHOP, increases the 
levels of DR5 mRNA. This leads to increased DR5 oligomerization and 
accumulation in the ER/Golgi, and promotes a Caspase 8-mediated programmed 
cell death (286) (Fig 7). 
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Figure 7. The two stages of ER stress. A) In resolvable ER Stress, the cell can respond 
with the activation of three pathways. The ATF6 can be cleaved in the cytosol and 
undergo nuclear translocation to activate genes related to chaperones and autophagy; 
IRE1alpha can promote the alternative splicing of XBP1 that will enhance the expression 
of genes associated to autophagy, lipid synthesis and ER chaperones; and IRE1alpha 
can also upregulate RIDD pathway that is responsible for mRNA degradation. Recent 
	 	 		
	 30	
data suggests that RIDD mechanism is crucial to maintain DR5 levels lower and avoid the 
activation of caspase pathways. On its turn, PERK can phosphorylate eiF2a that will act 
on ATF4 that will promote the expression of CHOP, a master player in ER stress. CHOP 
can increase the levels of DR5 mRNA levels and ATF4 can also, independently, increase 
the levels of proteins associated to autophagy, oxidative response and ER chaperones. B) 
Under unresolvable ER Stress conditions, several caspase pathways are activated. The 
better understood mechanisms is based on the increase of the DR5 mRNA levels due to 
the expression of CHOP that is not compensated by an increase in IRE1alpha and, 
subsequently, the RIDD pathway. The DR5 protein will then lead to the activation of the 
Caspase 8 pathway that culminates in caspase 3. Besides DR5, CHOP can also activate 
BAX and GADD34 and inhibit BCL-2 leading to apoptosis and ROS production. The 
IRE1alpha can, by itself, also promote apoptosis via the ASK/JNK pathway (286-289). 
 
1.5.1. α-Syn, ATP13A2 and ER homeostasis 	
ER stress has been intimately linked to neurodegenerative disorders (290, 291). In 
the SN of PD patients a notorious increase in UPR markers was reported (292) 
with a similar activation of this cellular response being found in neurotoxin models 
of PD, including 6-hydroxydopamine (6-OHDA) and 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyrine (293-296). 
α-Syn oligomers accumulate preferentially in the ER (297), and the protein 
appears to be an important intermediate in ER stress upon manganese-induced 
toxicity, via PERK pathway (298). In a PD mouse model, neurons displaying α-Syn 
pathology exhibit abnormalities in the ER morphology, accompanied by 
upregulation of ER chaperones (299, 300). Overexpression of WT and mutant 
(A53T) α-Syn promotes an impairment of the ER to Golgi trafficking leading to ER 
stress, ERAD impairment, Golgi fragmentation and ultimately cell death (139, 301, 
302). Also the α-Syn A53T mutant was associated to combined ER stress and 
mitochondria dysfunction (303), although the mechanisms underlying the ER 
stress component remain controversial (299). 
Conversely, knowledge regarding the interaction between ATP13A2 and this 
organelle is less extended. Since it is a transmembrane protein, its processing 
requires a passage via the ER before being targeted to the lysosome. In some 
familial mutations, a lost of cellular localization and accumulation in the ER was 
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reported and increased susceptibility to ER stress-promoting compounds (189) 
(Fig. 8E). 
 
	
Figure 8. The effect of α-Syn and ATP13A2 on the ER.  A) α-Syn oligomers have been 
found accumulated preferably in the ER. B) It has been described that α-Syn mediates 
Mn+ ER Stress and C) A53T α-Syn enhances cytotoxicity by promoting ER stress via 
PERK although the mechanism has not been fully validated.  D) Increased levels of WT 
and A53T α-Syn in yeast and mammalian cells can block ER-to-Golgi trafficking 
promoting ER Stress. E) Some mutations in ATP13A2 disable the capability of the protein 
to be targeted to the lysosome and accumulate in the ER. 								
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2. Aims of the study 
 
Several genetic alterations have been associated with familial forms of PD. It has 
been suggested that the molecular imbalance underlying the disease onset can be 
common among all genes, since alterations in them can promote the appearance 
of identical pathological hallmarks in patients. Therefore, it becomes essential do 
understand how PD-associated proteins intersect in the intracellular ecosystem 
and how alterations in one protein can affect the homeostasis of others. 
The objective of this thesis was to analyse the cellular interplay between two PD-
related proteins, ATP13A2 and α-Syn, and the effect of a selected mutation in the 
homeostasis of this interaction. For this purpose, we started by studying how a 
mutation in ATP13A2, Dup22, could affect α-Syn and in particular the latter 
protein’s propensity to oligomerize and aggregate. To achieve this goal we took 
advantage of pre-established cellular models that mimic both α-Syn 
oligomerization and aggregation. Additionally, using native α-Syn we confirmed 
the effect of ATP13A2 Dup22 on the α-Syn intracellular stability. 
Simultaneously, to understand if the interaction between the two proteins altered 
cellular homeostasis, we investigated several pathways and organelles that have 
been previously associated to PD. In detail, we analysed the endolysosomal 
pathway, the ER homeostasis and mitochondria stability. Ultimately, we studied if 
the interplay between the two proteins had an effect on the overall intracellular 
toxicity and if specific pro-apoptotic pathways were activated.  
In total, this study may provide new insights on the molecular mechanisms 
underlying the progression of PD and to better understand how two distinct 
disease-associated proteins can interact and influence cellular homeostasis.  	
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3.	Materials	and	Methods	
3.1. Plasmid constructs 
A total of 8 plasmids were used in the project as detailed in Table 2. 
 
Table 2. Plasmid constructs 
Protein Vector Reference 
GFP pcDNA 3.1+ NA 
ATP13A2 WT GFP pcDNA 3.1+ (189) 
ATP13A2 Dup22 GFP pcDNA 3.1+ (189) 
α-Syn pcDNA 3.1+ NA 
SynT pcDNA 3.1+ (304) 
Synphilin-1 pcDNA 3.1+ (304) 
 
3.2. Bacterial transformation and plasmid DNA purification 	
For transformation, the plasmid’s DNA was incubated with DH5 alpha competent 
bacteria on ice for 30 minutes, followed by a heat shock at 42ºC for 45 seconds 
and 2 minutes on ice. Afterwards the DNA was incubated in SOC-medium for 1 
hour at 37ºC. For large-scale purification with Nucleobond Xtra Midi (Macherey & 
Nagel, Germany), a 10 ml pre-inoculum in LB was prepared in the morning with 
the final LB volume of 100 ml being added overnight. 
 
3.3. Cell Culture and Transfections 	
Human H4 cells were maintained at 37°C and 5% CO2 in DMEM medium (PAN, 
Germany) supplemented with 10% Fetal Calf Serum and 1% penicillin-
streptomycin. Cells were seeded in different well-plate formats, one day prior to 
transfection and kept up to 48 hours after transfection.  
Transfections were performed with Fugene 6 (Roche, Germany), Metafectene 
(Biontex, Germany) or Calcium Phosphate. Fugene 6 and Metafectene 
transfections were done according to manufactures’ instructions. 
	 	 		
	 34	
For Calcium Phosphate transfections, 3-5 hours prior to transfection fresh cell 
medium was added to the cells. For transfection, DNA was diluted in 1xHBS buffer 
(25mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), 140mM 
NaCl, 5mM KCl, 0.75 Na2HPO4*2H20, 6mM Dextrose, pH 7.1). After properly 
mixed, 2.5M CaCl2 was added dropwise and vigorously mixed. Followed 20 
minutes of incubation, the mixture is added dropwise to the cells and the plate or 
dish gently rocked. The next morning, the medium was changed to avoid toxicity 
due to transfection procedure. 
Experiments using the α-Syn Bimolecular Fluorescent complementation (BiFC) 
were perform in H4 cells stability expressing the two hemis of the system: VN-α-
Syn and α-Syn-VC previously selected with G418 (Invivogen, USA) 
 
3.4. Immunocytochemistry 	
For immunofluorescence microscopy, cells were fixed with 4% parafolmaldahyde 
48 hours after transfection, sequentially treated with 0.5% Trinton X-100 and 1,5% 
normal goat serum or Bovine Serum albumin in Phosphate Buffered Saline (PBS). 
Primary antibodies were incubated in a 1:1000 solution overnight at 4ºC. 
Secondary Alexa Fluor antibodies were incubated for 2 hours at room temperature 
followed by Nuclei stained with Hoechst 33258 in a 1:5000 in PBS for 5 min. 
Images were captured, in a blind process, using a Leica DMI 6000B microscope 
(Germany) or Olympus IX81-ZDC (Germany) microscope and analyzed with 
Image J software (305). For counting the number of aggregates per cell, three 
different categories were chosen: cells with no aggregates, cells with less than 10 
aggregates and cells with 10 or more aggregates. 
NIAD-4 staining (Glixx Labs, USA), to identify the presence of amyloid-like 
structures, was performed by incubating cells with the dye at a final concentration 
of 10 μM for 30 min at room temperature followed by immunocytochemistry as 
previously described.  
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3.5. Live-cell imaging microscopy 	
For live imaging, cells were plated on µ-Dish 35 mm Ibidi dishes two days prior to 
transfection. Imaging was performed using an Olympus IX81-ZDC microscope 
under controlled conditions: 37ºC, 5% CO2 and 55-60% humidity. Recordings 
were performed up to 6 hours and started 6 hours after transfection. 
For investigating mitochondrial morphology, live-cell imaging was performed using 
Mitotracker® (Invitrogen, USA). Cells were incubated in PBS with a final 
concentration of 100nM of Mitotracker for 20 minutes at 37ºC. Black and white 
images of mitochondria were obtained using a macro for imageJ first described in 
(306). 
Living staining of lysosomes was performed using Lysotracker® (Invitrogen, USA). 
Cells were incubated in PBS for 30 minutes in a final concentration of 75 nM of the 
dye. Afterwards cells were analysed in the microscope without changing the 
media. 
Live imaging of membranes was performed using an FM Dye. Technically this dye 
allows the distinction between extracellular and intracellular membranes based on 
incubation time. A short period incubation of 5 minutes stains extracellular 
membranes while a longer incubation of 30 minutes followed by washing in PBS 
allowed the visualization of intracellular membranes.  
 
3.6. Immunoblotting analysis  	
For immunoblotting analysis, cells were incubated in lysis buffer (25mM Tris HCl 
pH 7.6, 150mM NaCl, 1%NP-40, 1% Sodium deoxycholate, 0.1% Sodium dodecyl 
sulfate) freshly supplemented with protease inhibitor cocktail (Roche, Germany) 
for 30 minutes on ice. After they were sonicated once for 10 seconds on ice and 
centrifuged at maximum speed (14000 rpm) for 10 minutes. The supernantant was 
collected and the pellet discarded. 
Protein quantification was done using the Bradford assay (307) with absorbance 
measurements performed in the Infinite M200 PRO plate reader (Tecan Ltd, 
Switzerland) at 595 nm. Before loading onto the gel, between 30μg to 60μg of 
protein was mixed with 5x Laemmli buffer (250mM Tris pH 6.8, 10% Sodium 
dodecyl sulfate, 1.25% Bromophenol Blue, 5% β-Mercaptoethanol, 50% Glycerol). 
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Cell lysates were electrophoresed through 12% or 15% sodium dodecyl sulfate 
polyacrylamide (SDS-PAGE) gels under denaturing conditions and transferred to 
nitrocellulose (GE Healthcare) or PVDF (Milipore) membranes for 2 hours using a 
regular wet transfer procedure using a 25mM Tris, 192mM Glycin with 20% 
methanol buffer. Afterwards the membranes were blocked either with 5% skim 
milk or 5% Bovine Serum Albumin in tris-buffered saline for 1 hour and were then 
incubated with primary antibodies overnight at 4°C. HRP-conjugated secondary 
antibodies were applied for 2 hour at room temperature in a 1:10000 dilution in 
tris-buffer saline. Between blocking and antibodies incubations, membranes were 
washed 3 times for 10 minutes with tris buffer saline with 1% Tween 20.  
Membrane visualization was performed on either an Alpha Imager (Alpha 
Innotech, USA) or Fusion Fx (Vilber Lourmat, France) with Immobilon Western 
Chemiluminescent HRP substrate (Merck Milipore, USA). Quantification of bands 
was performed using Image J software (305). 
 
Table 3. Primary antibodies used. 
Antibodies Species Company 
α-Syn 
Mouse BD Bioscience (USA) 
Rabbit Santa Cruz Biotech (USA) 
p-α-Syn Mouse Wako (USA) 
V5 Rabbit Abcam (UK) 
b-actin Mouse Sigma (USA) 
CHOP Mouse Thermo Scientific (USA) 
CatD Goat Santa Cruz Biotech (USA) 
Atg5 Rabbit Abcam (UK) 
GM130 Mouse BD Bioscience (USA) 
Calnexin Rabbit Gene Tex (USA) 
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Table 4. Secondary antibodies used. 
Antibodies Recognizing Company 
Alexa Fluor 555 Donkey 
Mouse 
Invitrogen (USA) Rabbit 
Alexa Fluor 633 Donkey Goat 
AMCA Goat 
Mouse Jackson Immunoresearch 
(USA) Rabbit 
ECL, HRP-Linked 
Mouse 
Amersham (UK) 
Rabbit 
ECL, HRP-Linked Goat 
Jackson Immunoresearch 
(USA) 
Atto 647N Mouse Sigma (USA) 
 
 
3.7. Proteinase K Resistance 	
Cells were collected 48 hours after transfection in phosphate buffer (1X PBS with 
1% TritonX-100). Lysates were sonicated for 10 seconds at 40-50% and 
afterwards incubated with 2,5ug/ml of freshly prepared Proteinase K for different 
time periods :0, 5 and 10 minutes. Finally the lysates were boiled at 95ºC for 5 
minutes and loaded onto 12% SDS-PAGE gels, and immunoblots were performed 
as previously described. 
 
3.8. Size Exclusion Chromatography and Dot blot 	
Cells were collected 48 hours after transfection in phosphate buffer (1X PBS with 
0,5% TritonX-100) freshly supplemented with protease inhibitor cocktail (Roche, 
Germany) and centrifuged for 10 minutes at 10,000g. 2-3mg of total protein in a 
maximum volume of 500ul was filtered using a 0,45µm Spin-X centrifuge filter 
before loading onto a Superose 6 (Superose 6 10/300GL. GE Healthcare Life 
Science, Sweden) column and subsequent processed by Size Exclusion 
Chromatography by high-performance liquid chromatography (SEC-HPLC) (Äkta 
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Purifier 10, GE Healthcare Life Science, Sweden). The run was performed with a 
flow rate of 0,5ml/min for 1.2 Column Volumes and a total of 56 fractions with 
500ul were collected. The theoretical molecular weight sizes for each fraction were 
assessed using a SEC standard (BioRad, USA). The standard is composed by 5 
proteins of known molecular weights: Vitamin B12 (1,35 kDa), Myoglobin (17 kDa), 
Ovalbulmin (44 kDa), γ-globulin (158 kDa) and Thyroglobulin (670 kDa) (Fig. 9A). 
For the dot blot assay, these fractions were boiled at 95ºC for 10 minutes and 
centrifuged at 10,000g for 5 minutes. Afterwards they were loaded to a 
nitrocellulose membrane with the schematic exemplified in Fig. 9B. 
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Figure 9. SEC-HPLC Gradient and Dotblot. A) A protein gradient was used as a 
standard to predict the approximate molecular weights of our samples. The run, with 1.2 
column volumes of length, generated a total of 56 samples that were labelled as A1 to 
A15, B1 to B15, C1 to C15 and D1 to D11. B) Schematics of how SEC-HPLC samples 
were loaded onto the dotblot apparatus.	
 
3.9. RNA extraction and cDNA synthesis 	
RNeasy Mini Kit (Qiagen, Germany) was used to extract and purify total RNA from 
H4 cells. RNA quality was determined spectrophotometrically, and RNA (300 ng) 
was reversed transcribed into cDNA, following genomic DNA removal, by using 
QuantiTect Reverse Transcription Kit (Qiagen, Germany) containing oligo-dT and 
random primers.  
 
3.10. Real-time PCR analysis 
 
Quantitative real-time polymerase chain reactions (qPCRs) were performed using 
a Mx300P cycler (Agilent Techonolgy, USA), and samples were prepared 
according to the Mesa Blue qPCR MasterMix Plus for SYBR Assay (Eurogentec, 
Belgium) protocol. For genes of interest, custom primers were designed and 
checked for target specificity using the bioinformatics Primer-Blast (308). The 
primers used can be seen in Table 5. 
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Table 5. Primers used for qPCR 
Gene  Sequence 
CHOP  Forward Primer 5’-AGTCTAAGGCACTGAGCGTA-3’ 
Reserve Primer 5’-TTGAACACTCTCTCCTCAGGT-3’ 
DR5 Forward Primer 5’-TGCTCTGATCACCCAACAAG-3’ 
Reserve Primer 5’-CTGAGATATGGTGTCCAGGTG-3’ 
ATP13A2 Forward Primer 5’-CAGTTTCATCCGTGAGGCT-3’ 
Reserve Primer 5’-CACGACGTGATAGCCGATGA-3’ 
α-Syn Forward Primer 5’-AGTGACAAATGTTGGAGGAG-3’ 
Reserve Primer 5’-GCTTCAGGTTCGTAGTCTTG-3’ 
β-actin Forward Primer 5’-GCGAGAAGATGACCCAGATC-3’ 
Reserve Primer 5’-GCGAGAAGATGACCCAGATC-3’ 
 
β-actin was used as RNA loading control after confirming consistent expression 
across all samples. For each gene, dissociation curves were verified and negative 
controls, both non-reversed RNA and no-template, were included in each plate to 
ensure specificity of the amplification. Samples from three independent 
experiments were loaded in triplicates and amplified as follows: 5 minutes at 95ºC, 
40 cycles of 30 seconds at 95ºC and 1.5 minutes at 60ºC. Relative quantification 
of targeted genes was calculated using the 2-ΔΔCt method (309). Briefly, Ct values 
from genes of interest were obtained via MxPro software and subtracted to the 
corresponding Ct value of β-actin (ΔCt). Fold-change expressions were 
subsequently calculated by subtracting ΔCt control sample (GFP transfected 
samples) to ΔCt of experimental condition (ΔΔCt). ANOVA was used to analyze 
significant changes in gene expression. 
 
3.11. Mitosox assay 
 
Cells were plated in 96-well plates and the experiments performed 48 hours after 
transfection. Cells were washed with PBS an incubated in Mitosox Red 
(Invitrogen) diluted in PBS for 20 minutes at 37ºC. Afterwards cells were once 
again washed in PBS and the signal (Exc: 510nm, Emi: 580nm) was measured 
with the Infinite M2000 PRO (Tecan, Mainz, Germany). Three basal 
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measurements were performed with the cells being challenged with 5% H2O2 up to 
30 minutes. 
 
3.12. Cytotoxicity assay 
 
Cytotoxicity was measured via release of Lactate dehydrogenase (LDH) into the 
culture medium with a commercial Cytotoxicity Detection Kit (LDH) (Roche, 
Germany). Basic LDH release was measured in non-transfected cells, the maximal 
LDH release was measured by cell lysis in 2% Triton X-100. Absorbance was 
measured with the Infinite M2000 PRO (Tecan, Mainz, Germany) plate reader at 
490 nm. Experimental values were calculated in percentages of the maximal LDH 
release and normalized to GFP as a control. 
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4. Results 	
 
 
 
 
 
 
 
The findings described in this section are a partial representation of the following 
publications: 
 
Guowei Yin*, Tomas Lopes da Fonseca*, Sibylle E. Eisbach, Ane Martín Anduaga, 
Carlo Breda, Maria L. Orcellet, Éva M. Szegő, Patricia Guerreiro, Diana Lazaro, 
Gerhard H. Braus, Claudio O. Fernandez, Christian Griesinger, Stefan Becker, 
Roger S. Goody, Aymelt Itzen, Flaviano Giorgini, Tiago F. Outeiro and Markus 
Zweckstetter (2014) alphα-Synuclein interacts with the switch region of Raba8a in 
a Ser129 phosphorylation-dependent manner. Neurobiol. Dis, 70C, 149 – 161. * 
Equal contribution 
 
Tomás Lopes da Fonseca, Raquel Pinho and Tiago F. Outeiro – A familial 
mutation in ATP13A2 enhances alpha-synuclein aggregation and promotes cell 
death. Accepted for publication Human Molecular Genetics. 
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4.1. The ATP13A2 Dup22 mutant exhibits altered intracellular 
localization  
 
ATP13A2 is a transmembrane protein that is found at the late endosomes and 
lysosomes (32). Considering that, throughout the project, we used ATP13A2 fused 
to GFP, we started by investigating if the cellular localization of the native protein 
was maintained. Live cell imaging using lysotracker showed that ATP13A2 WT 
fused with GFP is present in late endosomes and lysosomes, similarly to what has 
been described for non-tagged protein (Fig. 9A). The Dup22 mutation, that 
eliminates 6 of the 10 transmembrane domains, promoted a mislocalization of the 
protein as shown by loss of co-localization with lysotracker (Fig. 9B). 
This data confirms that the familial mutation Dup22 promotes a loss of intracellular 
localization in ATP13A2.  
 
	
Figure 10. Dup22 mutation alters ATP13A2 cellular localization. A) ATP13A2 WT co-
localizes with Lysotracker while B) its mutated version, ATP13A2 Dup22, loses its 
intracellular localization. Scale bar: 5 μm. 			
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 4.2. ATP13A2 Dup22 increases the propensity of α-Syn to aggregate in 
a cellular model 
 
α-Syn aggregation and deposition inside brain cells is one of the hallmarks of 
synucleinopathies. Nevertheless, this is one of the most difficult to recapitulate in a 
petri disk and, particularly, in cell cultures. To better understand the effect of the 
ATP13A2 Dup22 mutation on α-Syn aggregation we used one of the few well-
established cell-based models of α-Syn aggregation (304). Briefly, this model 
consists of the co-expression of SynT (α-Syn fused to an N-terminal fragment of 
GFP that renders α-Syn more prone to aggregation) and Synphilin-1 (Fig. 11A), an 
α-Syn-interacting protein that promotes α-Syn aggregation and is present in LBs in 
PD and other synucleinopathies. Co-expression of SynT and synphilin-1 results in 
the formation of intracellular inclusions (Fig. 11B) that share many of the features 
of LBs, such as Thioflavin S staining and co-staining with ubiquitin (304, 310). 
Using this model we observed that the ATP13A2 Dup22 mutation promoted two 
distinct effects: an increase in the percentage of cells with inclusions and an 
increase in the number of inclusions per cell (Fig. 11C). In contrast, the co-
expression of ATP13A2 WT promoted no significant alterations on inclusion 
formation (Fig. 11C). Both ATP13A2 WT and Dup22 were present within the 
inclusions formed (Fig. 11D). Despite the alteration on inclusion formation, no 
alterations in the protein levels of ATP13A2 or α-Syn were observed (Fig. 11E), 
suggesting a mutual effect between the two proteins that did not influence the way 
cells processed the inclusions. 
All together, these results indicate that ATP13A2 Dup22 mutation can drastically 
increase α-Syn aggregation propensity. Interestingly, this effect is independent of 
α-Syn protein levels. 
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Figure 11. Effect of ATP13A2 on α-Syn aggregation. A) Triple transfections were 
executed to analyse the effect of ATP13A2 on α-Syn aggregation. In detail, SynT and 
Synphilin-1 were co-expressed with GFP, ATP13A2 WT GFP or ATP13A2 Dup22 GFP. 
B) Representative images for each category of number of aggregates: no aggregates, 
less than 10 aggregates, 10 or more aggregates. C) Expression of ATP13A2 Dup22 
promoted an increased number of cells with aggregates and amount of aggregates per 
cell. D) ATP13A2 WT and Dup22 mutation co-localized with these proteinaceous 
intracellular inclusions (upper and lower painel, respectively). E) Immunoblot analysis 
revealed no difference in protein levels. All experiments are representative of N=3 
independent experiments. Data are mean ± S.D. ANOVA with post-hoc Turkey’s tests. * p 
< 0.05, ** p <0.01 and *** p < 0.001. Scale bar: 5 μm. 
 
As mentioned above, ATP13A2 is a transmembrane protein belonging to the 
Endolysosomal machinery (32). This pathway has gained attention in the PD field 
as a possible mechanism underlying the intracellular pathology of the disease 
(221). Given the notorious effect of ATP13A2 on α-Syn aggregation, we then 
investigated the impact of another important player in this pathway, Rab8a, on α-
Syn aggregation (237).  
Rab8a is a Rab GTPase member of the endolysosomal pathway at the Golgi level, 
and has been extensively associated with α-Syn (236).  
Taking advantage of the cellular model of α-Syn aggregation described above 
(Fig. 12A), we observed that Rab8a could also influence inclusion formation (Fig. 
12B) without altering the levels of α-Syn (Fig.12C). In vitro studies further 
corroborate the effect of Rab8a on α-Syn aggregation (Fig. 12D). Interestingly, 
using immunoprecipitation assays, we concluded that α-Syn and Rab8a could 
directly interact in vivo including in the synaptic terminals (Fig. 12E). In Nuclear 
Magnetic Resonance (NMR) experiments we observed that the C-terminus of α-
Syn is essential for this interaction and that this interplay was independent of 
Rab8a activity (Fig. 12F and G). 
These data further confirms that the endolysosomal pathway plays an important 
role on α-Syn homeostasis. Furthermore the direct interaction between α-Syn and 
Rab8a at the synaptic level might indicate that α-Syn could be a functional piece of 
this intracellular mechanism. 
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Figure 12. Rab8a modulates α-Syn aggregation in human cells. (A) Triple 
transfections were perfromed to analyse the effect of Rab8a on α-Syn aggregation. In 
detail, SynT and Synphilin-1 were co-expressed with GFP or Rab8a GFP. (B) Raba8a 
increases the total number of cells with aggregates when compared to the control, (C) 
without altering α-Syn total protein levels. D) In vitro studies, using recombinant protein, 
reveal that Rab8a can accelerate α-Syn aggregation and increase the amount of 
aggregated protein.  E) α-Syn was immunoprecitated (IP) from rat hippocampus or mouse 
cortical synaptosomes and aS and Rab8a were detected (IB). F) Rab8a binds to the C-
terminus of α-Syn. Averaged NMR chemical shift perturbation of 1H/15N resonances of α-
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Syn in the presence of Rab8a (GDP) and G) Rab8a (GppNHp) for molar ratios up to 1:10 
and 1:8 respectively of α-Syn/Rab8a. All experiments are representative of N=3 
independent experiments. Data are mean ± S.D. ANOVA with post-hoc Turkey’s test. * p 
< 0.05, ** p <0.01 and *** p < 0.001. 
The results described in Figure 12D, 12E, 12F and 12G were generated by 
colleagues from the labs of Prof. Dr. Tiago Outeiro’s and Prof. Dr. Markus 
Zweckstetter. 	
 
4.3. ATP13A2 Dup22 promotes the aggregation of SynT 
 
The previous model relies on the co-expression of SynT and Synphilin-1. The 
latter is a well-known interactor of α-Syn that can influence its cellular homeostasis 
(311). For this reason we performed identical experiments to those described 
above, but in the absence of Synphilin-1 (Fig. 13A). In these experimental 
conditions we also observed the formation of intracellular aggregates and, similarly 
to the previous model, ATP13A2 Dup22 promoted the formation of more inclusions 
per cell, and increased the percentage of cells with inclusions (Fig. 13B and C). In 
this paradigm, without the presence of Synphilin-1, we observed that ATP13A2 
WT also lead to an increase in the formation of inclusions (Fig. 13C), without 
altering the protein levels (Fig. 13D). The inclusions formed in this model, 
particularly upon the co-expression of ATP13A2 Dup22 and SynT, stained positive 
for phosphorylated α-Syn at residue serine 129 (p-α-Syn) and NIAD-4, a dye that 
binds to amyloid structures (312), two known markers of LBs (Fig. 13E and F). 
To further characterize the biochemical nature of the inclusions, we performed a 
proteinase K (PK) digestion assays. At the time points tested (0 minutes, 5 
minutes and 10 minutes), we observed that co-expression of both ATP13A2 
Dup22 and SynT resulted in a higher SynT resistance to PK treatment that was 
already noticeable after 10 minutes (Fig. 13G and H). 
To conclude, we prove that ATP13A2 Dup22 can enhance SynT propensity to 
aggregate. Additionally, we showed that these aggregates are positive for p-α-Syn 
and amyloid structures and that, at a biochemical level, ATP13A2 Dup22 can also 
increase SynT resistance to PK treatment. 
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Figure 13. Effects of ATP13A2 on SynT aggregation. A) Double transfections were 
executed to analyse the effect of ATP13A2 on SynT. In detail, SynT was co-expressed 
with GFP, ATP13A2 WT GFP or ATP13A2 Dup22 GFP.  . B) Expression of both WT and 
ATP13A2 Dup22 promoted the formation of SynT intracellular inclusions (middle and 
lower panel), even without the expression of Synphilin-1. C) Expression of ATP13A2 
Dup22 promoted an increase in number of cells with aggregates and the amount of 
aggregates per cell. In this transfection paradigm, also ATP13A2 WT promoted a similar 
effect. D) Despite the increase in the amount of aggregates, no alterations in protein 
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levels were detected by immunoblot. E) These aggregates stained positive for p-α-Syn 
and for F) NIAD-4, a marker for amyloid structures. G) Immunoblotting analysis for SynT 
reveals a higher resistance of the protein to PK treatment when co-expressed with 
ATP13A2 Dup22. H) Graphic representation of the effect of PK treatment. All experiments 
are representative of at least 3 independent experiments. Data are mean ± S.D. ANOVA 
with post-hoc Turkey’s test. * p < 0.05, ** p <0.01 and *** p < 0.001. Scale bar: 5 μm.  
  
4.4. ATP13A2 Dup22 promotes the formation of higher molecular 
weight species in a cell model of α-Syn oligomerization  	
The precise origin of α-Syn toxicity is still unclear. Nevertheless, as previously 
stated, two diverging hypothesis suggest that either (i) large insoluble protein 
aggregates or (ii) intermediate oligomeric species, as the main culprits in 
synucleinopathies. To understand if the effect of the ATP13A2 Dup22 was 
exclusive to the latter stages of α-Syn aggregation, we used another cell model to 
study the impact of ATP13A2 on α-Syn oligomerization, based on the BiFC assay. 
BiFC was first generated in 2002 and later optimize for the study of α-Syn 
oligomerization (146, 313). Briefly, the assay is based on the capability of the 
reconstitution of a split fluorophore upon interaction of two proteins (Fig. 14A).  
The majority of the studies using this assay use microscopy-based approaches in 
order to analyse changes in protein dimerization/oligomerization. This approach 
takes in consideration the assembly or disassembly of dimers, but does not 
provide direct evidence for the occurrence of changes in higher molecular species 
that were observed in the first report (146). To tackle this, we used SEC-HPLC 
followed by Dotblot analysis, and observed that the expression of ATP13A2 Dup22 
promoted an increase in the molecular weight α-Syn oligomeric species (Fig. 14B 
and C). The expression of ATP13A2 WT promoted no alteration in the molecular 
weight pattern of α-Syn oligomers (Fig. 14B and C) and no detectable alteration in 
total protein levels (Fig. 14D). Importantly, we also found that the increase in the 
size of the oligomeric species leads to increased intracellular toxicity (Fig. 14E). 
These data indicates that besides SynT aggregation, ATP13A2 Dup22 can also 
influence the initial steps of α-Syn oligomerization. Importantly, the formation of α-
Syn higher molecular weight species promoted by ATP13A2 Dup22 is associated 
to an increase in intracellular toxicity. 
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Figure 14. ATP13A2 Dup22 promotes the formation of high molecular weight α-Syn	
species. A) Triple transfections were executed to analyse the effect of ATP13A2 on α-
Syn oligomerization. In detail, the two BiFC constructs (α-Syn-VC and VN-α-Syn) were co-
expressed with GFP, ATP13A2 WT GFP or ATP13A2 Dup22 GFP.  B) ATP13A2 Dup22 
promoted the formation of high molecular weight α-Syn species, which appeared in early 
fractions of the HPLC, while no effect was observed with ATP13A2 WT. C) Graphic 
representation of α-Syn distribution throughout HPLC fractions, in all three experimental 
conditions. Total signal of all dots were calculated and individual dots were normalized to 
that sum. D) Immunoblot was performed with the same samples used for SEC-HPLC, and 
no differences in protein levels were detected. E) The formation of higher molecular 
weight species lead to the increase of cellular toxicity, measured by LDH release. All 
experiments are representative of 3 independent experiments. Data are mean ± S.D. 
ANOVA with post-hoc Turkey’s. * p < 0.05, ** p <0.01 and *** p < 0.001. 	
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4.5. ATP13A2 Dup22 promotes the formation high molecular weight 
species of untagged α-Syn 
 
The strong effect promoted by the ATP13A2 Dup22 mutation in the aggregation 
and oligomerization models prompted us to study the effect of this mutation on 
untagged α-Syn (Fig. 15A). Using SEC-HPLC, we observed that ATP13A2 Dup22 
could enhance the formation of α-Syn oligomeric species (Fig. 15B and C) without 
altering the amount of protein (Fig. 15D). For this set of experiments we performed 
an additional control that consisted in the application of recombinant α-Syn in the 
SEC-HPLC (Fig. 15E). Since α-Syn is not a globular protein, the time taken by the 
protein to pass through the column is shorter, resulting in its appearance in earlier 
fractions. Monomeric α-Syn is mainly present in fractions C3 to C8. According to 
the protein gradient (Fig. 9A), these fractions correspond to proteins with 
molecular weights ranging from 44kDa to 17kDa. 
The formation of higher molecular weight species by ATP13A2 Dup22 is also 
observed with untagged α-Syn. Combined, this date suggests that ATP13A2 plays 
a crucial role in all steps of α-Syn oligomerization and aggregation. 
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Figure 15. ATP13A2 Dup22 enhances the formation of higher molecular weight α-
Syn species, when co-expressed with untagged α-Syn. A) Double transfections were 
executed to analyse the effect of ATP13A2 on α-Syn. In detail, α-Syn was co-expressed 
with GFP, ATP13A2 WT GFP or ATP13A2 Dup22 GFP. B) ATP13A2 Dup22 enhances 
the formation of higher α-Syn molecular species that appeared in early fractions of the 
SEC-HPLC. Cells expressing both ATP13A2 WT or GFP and α-Syn exhibited similar size 
exclusion pattern. C) Graphic representation α-Syn size fractioning, from all three 
experimental conditions, confirming a shift in the molecular size of α-Syn in the presence 
of the mutated ATP13A2. D) Before SEC-HPLC, all samples were analysed by 
immunoblot that show no difference in protein levels. E) Recombinant untagged α-Syn 
was used as a control. All experiments are representative of 3 independent experiments. 
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Data are mean ± S.D. ANOVA with post-hoc Turkey’s test. * p < 0.05, ** p <0.01 and *** p 
< 0.001. 	
4.6. The formation of higher molecular weight α-Syn species is 
independent of CatD maturation 
 
Recently, a number of reports suggested that ATP13A2 is necessary for proper 
CatD maturation (163, 176, 264). As previously stated CatD is the most important 
protease when it comes to α-Syn degradation (250, 256). For this reason, we 
tested if the effects observed with untagged α-Syn (Fig. 15) and with the 
aggregation-prone form SynT (Fig. 13) were due to a decrease in total of CatD or 
to impairment in the maturation of the protease. 
We observed that, contrary to other reports, the formation of high molecular weight 
α-Syn species was independent of both levels and maturation of CatD, when co-
expressing untagged α-Syn together with ATP13A2 WT or Dup22 (Fig. 16A and 
B). An identical result was obtained when co-expressing SynT, suggesting that 
alterations in CatD are not involved in increased resistance to PK treatment (Fig. 
16C and D). 
All together, this data suggests that α-Syn oligomerization an aggregation 
promoted by ATP13A2 Dup22 is independent of the Endolysosomal pathway 
function and the maturation of its players. 
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Figure 16. ATP13A2 Dup22 effect on α-Syn is independent of CatD maturation. 
Levels of CatD were assessed in the presence of either α-Syn (A and B) or SynT (C and 
D). A) Immunoblot analysis for CatD revealed an identical protein levels in all tested 
conditions, with no significant differences on the B) total levels of CatD and levels of this 
proteases maturation (left and right graph, respectively). C) Identical results were obtained 
when SynT was co-expressed, instead of untagged α-Syn, with no differences observed 
in D) the total levels of CatD and in the ratio between mature and pre CatD (left and right 
graph, respectively). All experiments are representative of 3 independent experiments. 
Data are mean ± S.D. ANOVA with post-hoc Turkey’s test. * p < 0.05, ** p <0.01 and *** p 
< 0.001. 		
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4.7. ATP13A2 Dup22 and α-Syn co-localize in abnormal ER structures 
 
To understand the impact of the interaction between ATP13A2 and α-Syn in the 
overall cellular homeostasis, we took a deeper look at different organelles. We first 
noticed that both α-Syn and SynT co-localize with ATP13A2 Dup22 in an 
abnormal, reticular structure (Fig. 17A upper and lower panels, respectively). 
Importantly, this was not observed upon the expression of both forms of α-Syn 
with ATP13A2 WT, or when ATP13A2 Dup22 was expressed alone (Fig. 17B 
upper and lower panels, respectively and 10B). Taking advantage of an FM Dye 
that enables the distinction between plasma membrane and intracellular 
membranes, depending on the incubation time, we concluded that the abnormal 
structure was not composed of membranes derived from the plasma membrane, 
but, instead, was composed of intracellular membranes (Fig. 17C upper and lower 
panels, respectively). Lastly, we used immunocytochemistry to investigate the 
composition of the membrane structures. We found that those structures stained 
positive for an ER marker, Calnexin, and negative for the Golgi Network, as 
assessed with an antibody against GM130 (Fig. 17D and E). Interestingly, ER 
staining in cells co-expressing ATP13A2 WT and α-Syn exhibited a normal ER 
staining pattern, and no difference was detected in the Golgi Network (Fig. 17F 
and G).  
Combined, this data proves that ATP13A2 Dup22 and α-Syn can co-localize in 
abnormal membrane structures that are positive for the ER marker Calnexin. 
Importantly this network stained negative for other intracellular membrane 
structures. 
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Figure 17. ATP13A2 Dup22 and α-Syn co-localize with reticular, altered ER. A) 
ATP13A2 Dup22, together with α-Syn (upper panel) or SynT (lower panel), are found in 
abnormal cellular structures. B) These structures were absent in the presence of 
ATP13A2 WT either with α-Syn (upper panel) or SynT (lower panel). C) Microscopic 
visualization with a FM dye showing that those structures are not constituted by plasma 
membrane (upper panel) but intracellular membranes instead (lower panel). D) The 
structures stained positive for the ER marker Calnexin and E) negative for GM130, a Golgi 
marker. F) Normal ER was observed when co-expressing ATP13A2 WT with α-Syn and 
G) no difference was detected in the Golgi network. Scale bar: 5 μm. 
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4.8. Co-expression of ATP13A2 Dup22 and α-Syn promotes ER Stress 
 
The results described above suggested that the interplay between ATP13A2 
Dup22 and α-Syn could have a direct impact on ER homeostasis. The two 
proteins have been separately associated with the ER compartment (32, 299). 
Thus, we further investigated if the altered ER structures were associated with 
alterations in the homeostasis of this organelle. When analysing ER stress 
markers, we observed a notorious activation of the PERK pathway, measured by 
increased CHOP levels. The co-expression of ATP13A2 Dup22 and α-Syn 
promoted an increase in CHOP, both at the protein (4.87 ± 1.76) (Fig. 18A and B) 
as well as at the mRNA levels (12.62 ± 0.75) (Fig. 18C). Importantly, this pathway 
was not found activated when expressing each protein separately (Fig. 18A, B and 
C). A similar result was obtained when using SynT, suggesting that this effect can 
occur independently of the formation of inclusions (Fig. 18D, E and F). 
These results suggest that just the co-expression of α-Syn and ATP13A2 Dup22 
increases ER Stress. Importantly this effect appears to be independent of α-Syn 
aggregation since both untagged α-Syn and SynT promote an increase in CHOP 
levels. 
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Figure 18. The interplay between ATP13A2 Dup22 and α-Syn induces ER stress.  A) 
Immunoblot analysis revealed an increase in CHOP levels upon the co-expression of α-
Syn and ATP13A2 Dup22. B) Quantification of immunosignal for CHOP, showing 
statistically significant differences between α-Syn and ATP13A2 Dup22 group compared 
to all other conditions. C) An increase in CHOP mRNA levels was confirmed by RT-PCR. 
D) The co-expression of SynT with ATP13A2 Dup22 generated an identical increase in 
CHOP levels that, upon quantification E), was statistically different from all other 
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conditions. F) By RT-PRC we observed an increase in CHOP mRNA levels. All 
experiments are representative of 3 independent experiments. Data are mean ± S.D. 
ANOVA with post-hoc Turkey’s test. * p < 0.05, ** p <0.01 and *** p < 0.001. 		
4.9. ER Stress is accompanied by mitochondrial impairment 
 
 Mitochondria have a deep connection with neurodegeneration (314) including PD 
(315). Independently, both α-Syn and ATP13A2 has been associated with 
mitochondrial homeostasis and function (105, 156) and it is known that ER and 
mitochondria can physically interact (316). Therefore, we next tested if the 
interaction between the two proteins could alter the homeostasis of mitochondria.  
We measured the production of Reactive Oxygen Species (ROS) using Mitosox, a 
probe that once inside the mitochondria is oxidized by superoxide. We observed 
that, under basal conditions, the co-expression of α-Syn or SynT with ATP13A2 
Dup 22 did not alter ROS production (Fig. 19A, B, C and D). Nevertheless, the co-
expression of ATP13A2 Dup22 and α-Syn increased the susceptibility of cells to 
oxidative stress, leading to the generation of higher levels of ROS upon challenge 
with H2O2 (Fig. 19A, B, C and D). After obtaining these results, we assessed 
mitochondrial morphology. Using Mitotracker and a specific imageJ plugin that 
allows a better observation of the mitochondria structure by generating optimized 
black and white figures, we observed a clear shift in these organelles morphology 
between three distinct intracellular paradigms. Cells not transfected presented 
elongated mitochondria (Fig. 19E1), transfected cells with no alterations in the ER 
structure, that showed mainly elongated but already some rounded mitochondria 
(Fig. 19E2), and transfected cells with abnormal ER structure, where the majority 
of the mitochondria exhibited a round shape (Fig. 19E3). 
Together, these results show that the interplay between ATP13A2 Dup22 and α-
Syn can promote an increase in ROS production when under oxidative stress. 
Interestingly we could observe an alteration in mitochondria shape when the 
altered ER structure is detected. 
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Figure 19. Co-expression of ATP13A2 Dup22 and α-Syn alter mitochondrial 
homeostasis. A) The expression of ATP13A2 Dup22 together with α-Syn increases the 
generation of ROS under oxidative stress. B) Statistical analysis show no differences 
under basal conditions no differences, while 7.5 minutes after challenging the cells with 
H2O2. C) The same effect is observed with the co-expression of SynT with D) the first 
significant difference being obtained at the same time point. E) Mitochondria morphology 
was observed with Mitotracker. Black and white optimized images were obtained using an 
ImageJ plugin. Zoomed images of cells co-expressing ATP13A2 Dup22 and α-Syn show 
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that 1) untransfected cells present elongated mitochondria, 2) cells transfect but without 
abnormal ER structure show mainly elongated mitochondria but already some rounded-
shape ones and, finally 3) cells with the abnormal ER structure show the majority of cells 
with rounded mitochondria. All experiments are representative of N=3 independent 
experiments. Data are mean ± S.D. ANOVA with post-hoc Turkey’s test. * p < 0.05, ** p 
<0.01 and *** p < 0.001. Scale bar: 5 μm 	
4.10. Coexpression of ATP13A2 Dup22 and α-Syn increases 
cytotoxicity  
 
ER stress and mitochondrial impairment are intrinsically implicated in the overall 
cell homeostasis (317, 318). Considering our previous results, we asked whether 
those cellular alterations were associated with increased intracellular toxicity. By 
measuring the levels of LDH in the supernatant of these cells - a common 
measure of the membrane integrity and, hence, of cellular toxicity - we observed 
that the co-expression of ATP13A2 Dup22 together with α-Syn or SynT increased 
the cytotoxicity (Fig. 20A and B). Expressing the proteins separately did not 
produce the same effect, suggesting that the interaction between the two proteins 
is necessary to promote toxicity. Using live-cell imaging, we observed that the 
formation of abnormal ER structures precedes cell death, hinting that this 
organelle might be directly associated to the cell fate (Fig. 20C). A recent study 
concluded that increased CHOP levels could lead to unmitigated ER Stress that 
culminates in increase DR5 mRNA levels and, ultimately, in cell death (286). For 
this reason we analysed DR5 mRNA levels and concluded that the co-expression 
of ATP13A2 Dup22 with both α-Syn and SynT lead to a significant increase of 
DR5 mRNA levels (4.81 ± 0.55 and 3.48 ± 1.2, respectively) (Fig. 20D and E). 
Lastly, we observed that the interaction between ATP13A2 Dup22 and α-Syn 
increases intracellular toxicity. Furthermore, we observed an increase in the 
mRNA levels of DR5, which suggests an activation of apoptotic pathways. 
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Figure 20. The interaction between ATP13A2 Dup22 and α-Syn increases cellular 
toxicity. A) The co-expression of α-Syn with ATP13A2 promoted an increase in 
intracellular toxicity, measured by LDH release. B) An identical effect was observed with 
SynT. C) Live-cell imaging performed at different time-points showed that the formation of 
abnormal ER structures anticipated cell death. Importantly, increased DR5 mRNA levels 
were observed with when ATP13A2 Dup22 was expressed together with either D) α-Syn 
and E) SynT. All experiments are representative of N=3 independent experiments. Data 
are mean ± S.D. ANOVA with post-hoc Turkey’s tests. * p < 0.05, ** p <0.01 and *** p < 
0.001. Scale bar: 20 μm. 
	 	 		
	 78	
5. Discussion 
 
PD is a complex age-associated neurodegenerative disorder primarily known for 
its typical motor symptoms. However, despite intensive research, the molecular 
background and triggers of the disease remain mostly unknown (319). α-Syn 
aggregation in LBs and Lewy neurites is a classical histopathological feature 
shared between sporadic and familiar forms of PD, and deep efforts have been 
made to understand the molecular basis of the aggregation process (320). 
Deciphering which molecules or proteins can affect α-Syn aggregation might 
ultimately lead to the development of novel therapeutics for synucleinopathies. 
The cellular imbalance preceding α-Syn oligomerization and aggregation is elusive 
but impairment of the degradation pathways has been repetitively associated to 
this process (238, 321). Both proteasome and lysosome are involved in α-Syn 
degradation but only the latter organelle can effectively handle molecular species 
bigger than dimers (196, 239). ATP13A2 was the first lysosome-related protein to 
be found mutated in PD patients (Table 1), conferring extra notoriety to this 
organelle in the neurodegeneration context. This late endosome and lysosome 
transmembrane protein has been, since the beginning, associated to α-Syn 
homeostasis although the mechanisms underlying this effect are controversial 
(166, 193). An initial study using ATP13A2 KO mice described the formation of 
neuronal α-Syn aggregates (161). A recent work concluded that the accumulation 
of α-Syn is independent of the protein itself, since not all aggregates stained 
positive for α-Syn but were positive for ubiquitin (176). This new data suggests 
that the presence of α-Syn in these proteinaceous inclusions occurs after their 
formation and that α-Syn does not play an important role in their formation. 
Despite studies performed in conditions lacking ATP13A2 no work has, so far, 
addressed the effect of ATP13A2 familial mutations on its interaction with α-Syn. 
The present study aimed to understand the effect of a familial mutation in 
ATP13A2, Dup22, on α-Syn and how the interaction between the two proteins can 
affect intracellular balance. Taking advantage of a well-described cellular model to 
study α-Syn aggregation we concluded that ATP13A2 Dup22 could enhance this 
process by increasing both the number of inclusions per cell, and the number of 
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cells with these inclusions. Importantly, we have previously reported that these 
intracellular inclusions exhibit one of the main characteristics of LBs present in PD 
patients, amyloid structures (312). To further understand the importance of the 
endolysosomal pathway on α-Syn aggregation we studied another protein that has 
been recently linked to protein clearance and secretion via this mechanism: Rab8a 
(237). We were able to show that this TGN Rab GTPase can also influence α-Syn 
aggregation by enhancing, both in vitro and in vivo this cellular phenomena (312). 
Importantly, the effect of Rab8a is due to its direct interact with α-Syn, a process 
that requires the C-terminus of the latter. Together, this data strengths the 
hypothesis that the endolysosomal pathway plays an important role on α-Syn 
homeostasis. Furthermore the direct interaction between the two proteins 
suggests that α-Syn might have a functional role in this pathway. Reinforcing this 
theory is the fact that VAMP2, a known interactor of α-Syn, has also been 
connected to the endolysosomal machinery (116, 119). 
To further understand the effect of the Dup22 mutation of ATP13A2 on α-Syn 
aggregation we removed Synphilin-1 from the previously described model. 
Synphilin-1 is known to interact with α-Syn, and this protein could mask any direct 
effect promoted by ATP13A2 on α-Syn aggregation. For this reason we co-
expressed SynT with both ATP13A2 WT and Dup22, in the absence of Synphilin-
1. Here, we observed that ATP13A2 Dup22 could enhance the amount of cells 
with aggregates and, particularly, with large intracellular inclusions. ATP13A2 WT 
also increased the amount of intracellular inclusions, when compared to GFP, 
although to a much lesser extend when compared to ATP13A2 Dup22. 
Biochemically, ATP13A2 Dup22 promotes an increase in the resistance of SynT to 
PK treatment, a characteristic that was not observed when SynT was co-
expressed with ATP13A2 WT. Increased α-Syn resistance to PK treatment has 
been described in LBs and in α-Syn transgenic mice (322, 323). Furthermore, 
these inclusions presented similar characteristics to LBs found in PD patients, 
such as amyloid structures and S129 p-α-Syn (62, 63). Considering that both 
ATP13A2 WT and Dup22 can enhance SynT aggregation but just the latter 
increases SynT resistance to PK treatment suggests that the aggregates in the 
two conditions might have different conformations. On the other hand, the higher 
resistance to PK might be just the result of the significant increase in number of 
aggregates promoted by ATP13A2 Dup22. 
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Extensive research in PD, and more particularly on α-Syn, has so far failed to 
reach a consensus regarding which protein species induce intracellular toxicity 
and neurodegeneration (146, 147, 149, 150). Recent work shown that both 
oligomers and fibrils can promote a toxic effect and are partners in pathology 
development (151). Here we show that ATP13A2 Dup22 is able to promote the 
formation of higher molecular weight α-Syn species in a cellular oligomerization 
model. This effect was accompanied by an increase of intracellular toxicity. The 
observed effect promoted by ATP13A2 Dup22 in those different cellular models 
suggested that this mutation could modulate the overall homeostasis of α-Syn. To 
validate this hypothesis we performed experiments with untagged α-Syn and 
concluded that ATP13A2 Dup22 could also promote the formation of high 
molecular weight α-Syn species. This data proves that ATP13A2 Dup22 can 
influence α-Syn aggregation in all stages of the process either by promoting the 
formation of higher molecular weight species in untagged α-Syn and in the 
oligomerization model or by enhancing aggregate formation with SynT.  
The function of ATP13A2 is still unknown but physiological levels of the protein 
seem to be necessary for the proper maturation of CatD (163, 176, 264). CatD is 
one of the two aspartic proteases known to be present in cells (324). Once α-Syn 
is targeted for degradation via the lysosome, CatD is the main protease 
responsible for its clearance (250, 256). Furthermore, mutations in both ATP13A2 
and CatD are known to cause NCL (161, 186, 265, 325). Surprisingly, our 
immunoblot analysis showed no alterations in CatD maturation. We speculate that 
this result is due to the presence of endogenous levels of ATP13A2, which may be 
able to assure the proper maturation process of CatD. Since Dup22 is a loss of 
function mutation it is expectable that the generate protein would not interfere with 
the proper function of the endolysosomal machinery when endogenous ATP13A2 
is expressed. Our results suggest that the observed increase in oligomerization 
and aggregation promoted by ATP13A2 Dup22 is, at least partially, independent of 
the function of the endolysosomal pathway and from CatD maturation. 
Furthermore, and considering that different α-Syn species are degraded by 
different mechanisms one could speculate that the effect promoted by ATP13A2 
Dup22 in all α-Syn species might be independent of any degradation mechanism. 
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For a protein to exert its normal function it requires a critical process of folding to 
ensure that the proper conformation is achieved. The misfolding and aggregation 
of α-Syn has been, for many years, one of the main dogmas surrounding the study 
of PD pathology and PD-associated proteins (326). The folding machinery relies 
heavily on the ER and its chaperones and, therefore, this organelle has been 
extensively studied in PD context (290, 327). Additionally, the accumulation of 
misfolded proteins triggers an ER response, known as ER-stress, that consists in 
the UPR signalling cascade (289). This machinery can undergo two opposite 
responses, according to the degree of stress, that either culminate in cell survival 
or apoptosis (328). Despite prompting different fates, the molecular organizers are 
identical rendering hard to identify the triggers that can activate a pro-survival or a 
cell-death response. Here we show that α-Syn and ATP13A2 Dup22 can co-
localize in abnormal intracellular membrane structures that stained positive for 
Calnexin, a common ER marker. The ER specificity of these structures was 
confirmed using a marker for the Golgi network, GM130, which showed no co-
localization with the reticular structure. Moreover, we observed a normal ER 
distribution when co-expressing α-Syn with ATP13A2 WT, and no difference on 
Golgi network in all the conditions. 
The presence of ATP13A2 Dup22 at the ER membrane has been previously 
described (189). This mutation in ATP13A2 eliminates several transmembrane 
domains and promotes a mislocalization of the protein. Since transmembrane 
proteins are processed via the ER, before being targeted to their last cellular 
destination, ATP13A2 Dup22 appears to accumulate in this organelle. This 
mutation, along with others in ATP13A2, can sensitize cells to ER Stress (189). 
More interesting, though, is the presence of α-Syn in the ER upon its co-
expression with ATP13A2 Dup22. α-Syn typically presents an ubiquitous 
intracellular expression, but it has been described that toxic oligomeric α-Syn 
species can preferentially accumulate in the ER (297). This accumulation was 
reported in both α-Syn transgenic mice and in brain samples obtained from PD 
patients (297, 299). Nevertheless is still unknown if these oligomers are formed in 
the ER or if they are generate somewhere in the cell and then accumulate in this 
organelle. In the mice models, the presence of these species in the ER lead to 
chronic ER Stress and the activation of pro-apoptotic caspase cascades (299). A 
similar ER-mediated toxicity was observed in cell culture upon the overexpression 
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of mutant α-Syn A53T, together with mitochondrial impairment (303). Interestingly, 
as we described previously, ATP13A2 Dup22 can enhance the formation of α-Syn 
higher molecular weight species. One can speculate that these species are the 
ones accumulating with ATP13A2 Dup22 in the abnormal ER structures but further 
studies are required. 
The molecular mechanisms underlying ER Stress are commonly divided in three, 
according to their initiator at the membrane level. The PERK and IRE1alpha 
pathways are activated in both resolvable and unmitigated ER Stress while 
activation of ATF 6 cascade has only been described in the first type of response. 
From the trio, α-Syn has been particularly linked to the PERK pathway, since its 
intracellular presence is necessary for manganese-induced toxicity (298). As 
previously mentioned, PERK phosphorylates eiF2a that promotes the expression 
of CHOP, a major regulator of ER Stress (329). In our study, we prove that the 
accumulation of both ATP13A2 Dup22 and α-Syn at the ER leads to the activation 
of the PERK pathway that was measured by CHOP mRNA and protein levels. The 
fact that ATP13A2 Dup22 presence in the ER is not enough, per si, to increase 
CHOP level indicates that α-Syn accumulation at the ER is necessary to activate 
the PERK pathway. Additionally we observed that CHOP mRNA and protein levels 
with untagged α-Syn were higher when compared to SynT. This suggests that the 
intermediate oligomeric species that originate from the co-expression of ATP13A2 
Dup22 and α-Syn could be the main responsible for the observed ER Stress. 
 
In addition to the ER, other cellular organelles such as mitochondria, are thought 
to play a role in PD pathogenesis. The connection between mitochondria 
impairment and PD has been strengthen by both genetic and environmental 
causes (330). Mitochondria are the main cellular energy producers and also 
responsible for nearly 90% of the intracellular ROS production (331). ROS are 
oxygen species formed by the partial reduction of oxygen that can impact several 
cellular pathways such as iron homeostasis, cell proliferation and survival, and 
DNA damage (332). In normal conditions, ROS are important members of 
intracellular signalling but an imbalance on its production can lead to their 
accumulation and deleterious action. Some speculate that this imbalance can be 
easily reached in dopaminergic neurons due to tyrosine hydroxylase (333) since it 
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has been shown that tyrosine hydroxylase is an additional mechanism for 
intracellular ROS production (334). 
Some studies report that α-Syn can be found in both outer and inner mitochondria 
membranes (335, 336). It has been suggested that α-Syn contains, in its N-
terminus, a hidden mitochondrial localization sequence, and that its presence in 
this organelle can decrease the complex I activity (336). Moreover, mitochondrial 
α-Syn may impact the organelle movement, fusion and fission but the mechanisms 
underlying this effect are still arguable (337, 338). ATP13A2, on its turn, has been 
extensively associated with mitochondria, either by influencing the degradation of 
the organelle or due to its interaction with metals, particularly with Zn2+ and Mn+ 
(156, 159, 160, 170).  
Due to the intimate cross talk between ER and the mitochondria, and the role of 
both α-Syn and ATP13A2 on mitochondrial homeostasis, we investigated whether 
the interplay between these two proteins could promote mitochondria dysfunction. 
Here we show that the interaction between ATP13A2 Dup22 and α-Syn sensitizes 
cells to oxidative stress by increasing the production of ROS, more specifically 
superoxide, upon H2O2 challenge. Interestingly, no alterations were observed in 
basal levels, compared to all other conditions, suggesting that this effect might not 
be primordial in the cascade of intracellular events promoted by the interplay 
between these proteins. Furthermore, we concluded that both untagged α-Syn and 
SynT had an identical effect, with both significantly increasing ROS production. 
This indicates that, in terms of superoxide production, the existence intracellular 
aggregates do not represent an additional factor underlying ROS production. 
Mitochondrial morphology is crucial for cell physiology, and it has been shown that 
changes in mitochondria shape are associated with neurodegeneration and can 
lead to increased ROS production (339). By incubating our cells with Mitotracker 
we observed that cells displaying ER-reticulated network also exhibit loss of 
normal mitochondria shape. Our results indicate that the interplay between 
ATP13A2 Dup22 and α-Syn lead to changes in mitochondria morphology, from 
typical elongated to round, may be responsible for increased ROS production. 
Ultimately, we wanted to understand if the observed cellular effects would promote 
an overall alteration of the intracellular toxicity. We verified that the interaction 
between ATP13A2 Dup22 and α-Syn or SynT lead to increase LDH release, an 
indicative of higher intracellular toxicity. This result confirms that the presence of 
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both proteins, ATP13A2 Dup22 and α-Syn, at the abnormal ER structures is 
necessary for triggering the cellular stress that culminates in cell death. Taking 
advantage of time-lapse imaging we observed that the formation of the abnormal 
ER structures preceded cell death. A recent study has described that the balance 
between the activation of a pro survival or apoptotic ER stress response has on 
DR5 mRNA levels an important tipping point (286). Briefly, PERK and IRE1alpha 
pathways can compensate each other in order to provide a pro-survival response, 
by maintaining DR5 mRNA levels low. Nevertheless, upon unmitigated and 
chronic ER stress situations, CHOP promotes the upregulation of DR5 mRNA 
levels that cannot be attenuated by the RIDD mechanism of the IRE1alpha 
pathway. We observed that the co-expression of ATP13A2 Dup22 with α-Syn or 
SynT promoted a significant increase in DR5 mRNA levels. The expression of the 
proteins separately did not lead to this effect suggesting that, once again, the 
presence of both proteins at the ER is necessary to increase the DR5 mRNA 
levels and activate pro-apoptotic responses. 
These results highlight the role of endolysosomal proteins in α-Syn homeostasis, 
as both Raba8a and ATP13A2 are able to modulate the aggregation propensity of 
α-Syn. We show that a PD-associated mutation in ATP13A2 (Dup22) can promote 
the formation of high molecular weight α-Syn species and that the interaction 
between these two proteins can initiate a cascade of events that culminate in cell 
death. In detail, ATP13A2 Dup22 and α-Syn co-localize in abnormal ER structures 
and induce ER Stress that is accompanied by alteration in mitochondria 
morphology and homeostasis. Ultimately, we conclude that these deleterious 
effects culminate in increased intracellular toxicity via increased DR5 mRNA levels 
and the activation of pro-apoptotic mechanisms. 
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6. Conclusions and Outlook 
 
α-Syn intracellular dynamics is one of the most studied topics in PD and 
synucleinopathies. The complex and far-reaching network that encompasses this 
protein has dazzled researchers for near a quarter of a century and many 
questions are still unsolved. 
In this study, we explored the effect that endolysosomal proteins can have on α-
Syn intracellular homeostasis. We started by showing that an important protein of 
this pathway, Raba8a, could influence α-Syn aggregation in vivo and in vitro. We 
further focused our attention on another player of the pathway, ATP13A2, and a 
mutated version, ATP13A2 Dup22, consisting on a 22 base pairs duplication in the 
ATP13A2 gene sequence. This mutation has been described in an early-onset PD 
case and generates a shorter protein, due to the lost of several transmembrane 
domains, that presents an erroneous intracellular localization at the ER.  
Taking advantage of an α-Syn version that is prone to aggregate (SynT), we 
observed that ATP13A2 could enhance its aggregation and that ATP13A2 Dup22 
increased the resistance of SynT to PK digestion. Furthermore, using SEC-HPLC 
we show that the presence of ATP13A2 Dup22 enhanced the formation of higher 
molecular weight α-Syn species, both a pre-establish oligomerization model and 
when co-expressed with the untagged protein. Interestingly, the effect promoted 
by ATP13A2 Dup22 was independent of CatD maturation, a process in which 
ATP13A2 is known to play an important role. We speculate that endogenous 
ATP13A2 is sufficient to guarantee the normal maturation and CatD, which 
suggests that alternative mechanisms may underlie the effect of ATP13A2 Dup22 
on α-Syn. In future studies it would be interesting to knockdown endogenous 
ATP13A2 to better understand the overall impact of the Dup22 mutation on α-Syn 
oligomerization and aggregation. 
Besides an impact on aggregation and oligomerization, we prove that the interplay 
between α-Syn and ATP13A2 Dup22 has a deleterious effect in cellular 
homeostasis. We show that both proteins can co-localize in abnormal ER 
structures leading to a significant increase in ER Stress, particularly the PERK 
pathway, an effect that is only observed upon the co-expression of both proteins. 
Changes in the ER pattern are accompanied by alterations in mitochondria 
	 	 		
	 86	
homeostasis. We show that ATP13A2 Dup22 and α-Syn sensitize cells to 
oxidative stress by enhancing the production of ROS upon challenge with H2O2. 
This effect was observed both in the presence and absence of inclusions 
suggesting that, in this paradigm, these species may not the main cause behind 
mitochondrial functional impairment and altered morphology. In further 
experiments, in would be worth investigating other ER stress pathways and to 
understand if the mitochondria impairment is caused by the overall intracellular 
imbalance or by the direct interaction with the ER (316).  Additionally, it would be 
interesting to understand which α-Syn species are accumulating in the ER by 
taking advantage of α-Syn antibodies that can recognize different species of the 
protein.  
Finally, we show that the interaction between ATP13A2 Dup22 and α-Syn 
promotes the upregulation of DR5 mRNA levels, and increase of cellular toxicity. 
Moreover, we discovered that the formation of the abnormal ER structures 
precedes cell death. Additional work is necessary to further understand the 
mechanisms underlying cell death and which caspase pathways lead to the 
apoptotic-like phenotype. 
Altogether, our study provides new hints on how endolysosomal pathway can alter 
α-Syn homeostasis. We show that two proteins crucial in different stages of this 
degradation and secretion pathway, ATP13A2 and Rab8a, can alter α-Syn 
aggregation. Additionally, we bring a new insight on how the interaction between 
two PD-associated proteins, ATP13A2 and α-Syn, can lead to cellular death. In 
particular we show that the interplay between the familial mutation Dup22 in 
ATP13A2 and α-Syn can promote unmitigated ER stress, mitochondria impairment 
and the activation of apoptotic pathways. This knowledge provides a better 
understanding of the molecular interconnections underlying PD pathology and 
unveils new possible targets for a therapeutic approach.  								
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